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The immuno-inflammatory response in cardiometabolic diseases 
Cardiometabolic diseases, collectively represented by cardiovascular and metabolic 
diseases (obesity and diabetes), remain the leading cause of global mortality, 
accounting for about 1 in every 2 adult deaths worldwide. 
Inflammation has been addressed as the key feature of cardiometabolic diseases; 
however, compared to the classical, short-term inflammatory response, described as 
the principal response of the body invoked to deal with injuries (the hallmarks of 
which include swelling, redness, pain and fever (tumor, rubor, dolor and calor) [1]), 
the inflammation in cardiometabolic diseases is a long term, often referred as low-
grade, inflammation associated with detrimental consequences. This condition is 
principally triggered by nutrients and metabolic surplus, and engages a similar set of 
molecules and signaling pathways to those involved in classical inflammation [2]. 
Therefore, inflammation can be classified in distinct forms of injury responses or 
subclasses, as the case of the short-term or low-grade inflammation compared to the 
acute inflammation; otherwise, the low-grade immuno-inflammatory response, 
triggered by the metabolic surplus and closely associated with cardiometabolic 
diseases, can be described with new terms, as “metaflammation”, defined as the 
metabolically triggered inflammation [2] (Figure 1), or “immunometabolism”, 
referred as the ability of systemic and intracellular metabolism to drive innate and 
adaptive immune response [3]. 
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Pentraxin superfamily 
Pentraxins are a superfamily of essential components of the humoral arm of innate 
immunity and are evolutionarily conserved proteins characterized by a structural 
motif, in their carboxy-terminal, of a 200 amino acid with an 8 amino acid–long 
conserved pentraxin signature (HxCxS/TWxS, where x is any amino acid), referred 
as the pentraxin domain [4-6]. Their conservation is testimony to their role in 
complex organisms. Pentraxins recognize a wide range of exogenous pathogenic 
substances, altered self molecules and, in species-specific manner, behave as acute 
phase proteins. Based on the primary structure of the subunits, pentraxins are divided 
in short and long pentraxins [7-9] (Figure 2). 
Short pentraxins 
Short pentraxins are 25-kDa proteins characterized by a common structural 
organization generally in five or ten identical subunits arranged in a pentameric 
radial symmetry. Prototypic short pentraxins are CRP and SAP which share 
approximately 51% amino acid sequence identity and are thought to have originated 
from a single gene duplication [10]; however, CRP and SAP sequence and regulation 
have diverged between mouse and human, with CRP being an acute phase proteins in 
man and SAP in mouse [11]. In healthy adults plasma levels of CRP are barely 
detectable (≤3 mg/l), but they increase as much as 1000-fold following an acute-
phase stimulus as a result of accelerated rates of transcription in the liver, mainly in 
response to the pro-inflammatory cytokine IL-6 [5]; for this reason, CRP plasma 
levels have been used clinically for 75 years as a nonspecific systemic marker of 
infection, inflammation, and tissue damage. Although CRP mRNA expression in 
other tissues has also been reported, apparently extra hepatic sources of CRP do not 
contribute to its plasma levels [11]. Similarly, SAP is produced exclusively by 
hepatocytes and is the main acute-phase protein in mice, whereas in human serum it 
is constitutively present at 30 to 50 mg/L [11].  
The physiological functions attributed to short pentraxins involve the recognition and 
binding to different ligands, mostly in a Ca
2+
-dependent manner: various 
microorganisms (including fungi, yeasts, bacteria, and parasites through 
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phosphorylcholine (PC) and carbohydrate structures, promoting phagocytosis and 
resistance to infections) [12]; damaged and apoptotic cells, favoring their clearance 
[5]; the first component of complement C1q, activating the classical complement 
pathway [13]. Furthermore, CRP binds to modified low-density lipoprotein (LDL) 
via the PC and cholesterol moieties present on LDL [14] and colocalizes with LDL 
in human atherosclerotic lesions, but studies in mouse models of human 
atherosclerosis failed to address a atheroprotective or proatherogenic role of CRP 
[15]. Instead, only SAP binds to matrix components such as laminin, type IV 
collagen, fibronectin, and proteoglycans, to the β-amyloid peptide in a Ca2+-
dependent manner and contributes to the pathogenesis of amyloidosis [16]. 
Long pentraxins: PTX3 
The long pentraxin 3 (PTX3) is the prototype of the long pentraxin family. Members 
of this family were identified in the 1990s as cytokine-inducible genes or molecules 
expressed in specific tissues: guinea pig apexin in spermatozoa [17, 18], neuronal 
pentraxin (NP) 1 or NPTX1 [19, 20], NP2, also called Narp or NPTX2 [21, 22], and 
neuronal pentraxin receptor (NPR), a transmembrane molecule in neurons [23, 24].  
The PTX3 protein is 381 amino acids long, with a  molecular weight of 45 kDa and 
consists of a C-terminal 203 amino acids pentraxin-like domain coupled with an N-
terminal portion of 178 amino acids unrelated to other known proteins [8]. A single 
N-glycosylation site has been identified in the C-terminal domain of PTX3 at 
Asn220, which is occupied by complex type oligosaccharides, mainly fucosylated 
and sialylated biantennary sugars with aminofraction of tri- and tetrantennary 
glycans; changes in the relative content of bi-, tri-, and tetrantennary 
oligosaccharides and the level of sialylation are highly variable amongst PTX3 
isolates from different cellular sources, thus influencing biological activities where 
glycosylation pattern has functional implication [25]. Furthermore, human PTX3, 
beyond a typical multimeric organization, shows a complex quaternary structure with 
eight protomer subunits assembled into high order oligomers stabilized by disulfide 
bonds [25] and evidence has proved that the quaternary structure of this long 
pentraxin is fundamental in mediating its binding properties and, ultimately, its 
biological functions [26]. 
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PTX3 differs from CRP and SAP also for gene organization, cellular source and 
ligand-binding properties. Unlike the classic short pentraxins CRP and SAP, whose 
sequence and regulation have diverged from mouse to man, PTX3 is highly 
conserved in evolution and share 82% of identical amino acids and 92% of conserved 
amino acids. Thus, results obtained using genetic approaches in the mouse are likely 
to be informative for the function of PTX3 in man [8].  
A variety of cells, as endothelial cells (ECs), smooth muscle cells (SMCs), 
adipocytes, fibroblasts, mononuclear phagocytes, and dendritic cells (DCs) [27-35] 
can produce PTX3 in vitro upon exposure to primary inflammatory signals. PTX3 
production is induced by primary inflammatory signals, such as IL-1, TNFα, and 
microbial moieties (e.g., LPS, lipoarabinomannans) [27, 36]; specifically, agonists 
for different members of the TLR family, microbial moieties (LPS, OmpA, and 
lipoarabinomannans), and intact microorganisms stimulate PTX3 production [37], 
while IL-6 is generally a poor inducer of PTX3 [31]. However, different signaling 
pathways can affect PTX3 production, depending on cell type and/or stimuli: 
oxidized and enzymatically modified low density lipoproteins (ox-LDL) promote 
PTX3 production in ECs and human primary vascular smooth muscle cells [38]; 
IFN-γ inhibits PTX3 production in DCs, monocytes, and macrophages, while IL-10 
amplifies LPS-induced its expression [39, 40]; the NF-κB pathway controls PTX3 
expression in an experimental acute myocardial ischemia [41], while high-density 
lipoproteins (HDL) requires the activation of the PI3K/Akt pathway through G-
coupled lysosphingolipid receptors [42]; finally, glucocorticoid hormones (GCs) 
induce or enhance PTX3 production in non-hematopoietic cells (fibroblasts and 
ECs), but inhibit PTX3 production in hematopoietic cells (DCs and macrophages) 
[43]. Neutrophils constitutively store PTX3 in specific granules and release the 
protein, which partly localizes in neutrophil extracellular traps (NET), in response to 
TLR engagement by microorganisms or TLR agonists [40, 44, 45],  where it can 
contribute to the generation of an antimicrobial microenvironment essential to 
trapping and killing microbes [46, 47].  
PTX3 has been described to play a complex, non-redundant role in vivo, recognizing 
a diverse range of pathogens, modulating complement activity by binding C1q and 
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facilitating pathogen recognition by macrophages and DCs, thus proposing PTX3 as 
a multifunctional protein at the crossroads between immunity and inflammation, 
extracellular matrix construction and female fertility [8, 48]. 
PTX3 and the immuno-inflammatory response 
Similar to the short pentraxins, PTX3 can bind a variety of ligands, one of the best 
described is the first component of the complement cascade C1q [49, 50]: activation 
of the classical complement cascade is observed in vitro when PTX3 interacts with 
surface-immobilized C1q; on the contrary, inhibition is observed when interaction 
occurs in the fluid-phase, thus addressing at a dual role of PTX3 which enhances the 
clearance of bound-material, such as microbes, while on the other hand it may 
protect against unwanted complement activation in the fluid phase [51]. PTX3 bind 
specific pathogens, such as fungi, bacteria and virus, promoting phagocytosis and 
consequent clearance of the pathogen (conidia of Aspergillus fumigatus, 
Pseudomonas aeruginosa, Salmonella typhimurium, Paracoccidioides brasiliensis, 
zymosan; selected Gram positive and Gram negative bacteria as Staphylococcus 
aureus, Pseudomonas aeruginosa, Salmonella thyphimurium, Neisseria 
meningitides) [52-54], but not LPS. Indeed, in vivo studies with PTX3 deficient mice 
showed that PTX3 plays non-redundant roles in innate resistance to infections caused 
by these microorganisms, and for some of them the protective role of PTX3 is 
mediated by complement [52], however, PTX3 deficiency does not cause a 
generalized impairment of host resistance to microbial pathogens but it seems to be 
involved in recognition and resistance against specific microorganisms [8]. 
PTX3 may also play a regulatory role in inflammation as an increased resistance to 
LPS toxicity and to cecal ligation and puncture has been observed in PTX3 
transgenic mice [55]. Furthermore, PTX3 deficiency has been associated to more 
severe tissue damage in experimental models of kainate-induced seizures [56], 
cardiac ischemia and reperfusion [41], pleurisy and acute lung and kidney injury [57, 
58]. The regulated expression of this molecule in macrophages and DCs suggests that 
PTX3, unlike the short pentraxins made in the liver, represents a mechanism of 
amplification of innate resistance against pathogens mainly acting locally at the site 
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of infection and inflammation [8]. However, PTX3 plasma levels are low (about 25 
ng/mL in mice, <2 ng/mL in humans) in normal conditions but increase rapidly (peak 
at 6–8 h) and dramatically (200–800 ng/mL) during endotoxic shock, sepsis, and 
other inflammatory conditions [59, 60], possibly reflecting a role in the pathogenesis 
of damage, such as by amplifying the complement and coagulation cascades [50, 61]. 
PTX3 as a component of the extracellular matrix 
The most robust observation that PTX3 is a component of the extracellular matrix 
came from the finding that PTX3 deficient mice displayed a severe defect in female 
fertility [52, 62], ascribed to an abnormal cumulus oophorus, characterized by an 
unstable extracellular matrix in which cumulus cells were uniformly dispersed 
instead of radiating out from a central oocyte [63]. During cumulus matrix assembly 
the heavy chains of serum inter α trypsin inhibitor (IαI) protein bind covalently to 
hyaluronic acid (HA) or to the HA-binding glycoprotein TSG-6 and indeed, mice 
deficient in the light chain of IαI, bikunin [64], or in TSG-6 [65] are infertile because 
of instability of the cumulus matrix and lack of oocyte fertilization, like PTX3 
deficient mice. PTX3 and TSG-6, which are synthesized by cumulus cells [62], 
interact at a site distinct from TSG-6 HA-binding surface [63]. Therefore, 
PTX3/TSG-6 complexes might thus serve as anchoring sites for multiple HA 
molecules, thereby substantially strengthening and stabilizing the HA network. It has 
been shown that the interaction with HA is critical for the formation and stability of 
extracellular matrix in several tissues, both in physiological and pathological 
conditions [66, 67], thus suggesting a similar localization and function of PTX3 in 
certain HA-enriched inflammatory tissues [68, 69]. 
In a different experimental setting, PTX3 was shown to play a non-redundant role in 
the orchestration of tissue repair and remodeling: after tissue injury, PTX3 interacts 
with fibrinogen/fibrin and plasminogen at acidic pH promoting fibrin degradation, 
which is an essential step in tissue remodeling and scar formation [70].  
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PTX3 and cardiovascular diseases 
Recently a role of PTX3 in cardiovascular diseases has been addressed as the protein 
was detected in the myocardium and in the vasculature under different pathological 
conditions which was paralleled by the observation of increased plasma PTX3 levels 
in patients with cardiovascular disorders [71]. So far a role for PTX3 was described 
in the context of angiogenesis, vascular restenosis, atherosclerosis, and myocardial 
infarction (Figure 3).  
Angiogenesis and restenosis 
PTX3 was shown to dampen fibroblast growth factor-2 (FGF2)-dependent ECs 
proliferation [72] in vitro, thus inhibiting angiogenesis [73, 74]. Transfection of 
PTX3 in normal microvascular endothelial cells (MVECs) blunts their angiogenic 
properties, while PTX3 silencing by small interfering RNA restores the ability of the 
cells to produce capillaries and promotes angiogenesis [75]. This effect depends on 
the ability of PTX3 to bind with high affinity and selectivity FGF2, which in turn 
results in the inhibition of the interaction of FGF2 with tyrosine-kinase receptors 
(FGFRs) and heparin sulphate proteoglycans (HSPGs) on the surface of ECs and 
SMCs, thus dampening the generation of the proangiogenic complex 
HSPG/FGF2/FGFR [74, 76].  
The FGF/FGFR system plays also a crucial role in SMC proliferation, migration, and 
survival in vitro [77-80], and neointimal thickening after arterial injury in vivo [81, 
82]. These processes are critically involved in restenosis, the process of blood vessel 
narrowing that frequently occurs after percutaneous transluminal coronary 
angioplasty of atherosclerotic arteries. Experimental data confirmed that the 
overexpression of PTX3 in vivo or exogenously added PTX3 in vitro resulted in the 
inhibition of FGF2-dependent SMCs proliferation. This effect was associated with 
the suppression of the mitogenic and chemotactic activities exerted by endogenous 
FGF2 on SMCs, sequestering the growth factor in an inactive form [76].  
The FGF-binding domain was identified in the PTX3 N-terminus by monoclonal 
antibodies and surface plasmon resonance analysis [74], while TSG6, the secreted 
product of tumor necrosis factor-stimulated gene, was shown to revert the inhibitory 
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effects exerted by PTX3 on FGF2-dependent angiogenesis through the interaction 
with the N-terminal domain of PTX3 [83]. 
These observations suggest that PTX3 could act as an “FGF2 decoy” and may 
represent a potent inhibitor of the autocrine and paracrine stimulations exerted by 
FGF2 on ECs and SMCs and point to a novel therapeutic role of PTX3 in the 
treatment of restenosis after angioplasty [84]. 
Atherosclerosis 
PTX3 was detected in advanced atherosclerotic lesions on lumen surface as well as 
within the atherosclerotic plaque, in both animal models and in humans [85, 86]. 
Cholesterol accumulation in the intima of the vessels, the major pathological feature 
of atherosclerosis, is associated with the induction of an immune-inflammatory 
response resulting in the recruitment of monocyte/macrophages, PMNs (polymorph 
nuclear cells) and in the activation of ECs, which produce PTX3 in response to 
inflammatory stimuli normally associated with atherogenesis, as IL-1 and TNFα [87-
89]. Furthermore, neutrophils and monocytes/macrophages contribute to the large 
amount of PTX3 observed in arterial thrombi and aortic tissue in patients with 
different degrees of atherosclerosis with acute myocardial infarction [90]. PTX3 
expression, similar to that of CRP, is increased also in coronary plaques of patients 
with unstable angina pectoris (UAP) compared to those with stable angina (SAP). 
Nevertheless, PTX3 and CRP distribution is different; PTX3 expression is increased 
in complicated plaque compared to fibroatheroma, while the opposite is true for 
CRP; moreover abundant PTX3 was detected in intraplaque hemorrhage, while CRP 
staining was more intense in lipid rich plaque. Finally PTX3 is highly expressed in 
CD163-positive areas which normally marks anti-inflammatory M2 macrophages 
[91]. 
A causal role of PTX3 during atherogenesis was addressed in PTX3/apolipoprotein E 
(apoE) double knockout mice [85]. Normally mice are poorly susceptible to 
atherosclerosis [92]; therefore, the effects of the deficiency or the overexpression of a 
protein have to be tested in mice with a background susceptible to atherosclerosis. 
For this reason, specific transgenic mice were generated and among them, mice 
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lacking apoE or LDL-receptor are widely used [92-94]. PTX3 KO/apoE KO mice 
developed larger atherosclerotic lesions compared to apoE KO, an observation that 
was coupled to increased macrophage accumulation, increased bone marrow 
monocytosis, and, interestingly, increased expression of adhesion molecules, 
cytokines, and chemokines in the vascular wall. These findings suggested an 
increased immune-inflammatory response in PTX3 KO/apoE KO mice compared to 
apoE KO animals, demonstrating an athero-protective role of the protein [85]. The 
atheroprotective role of PTX3 was further confirmed by the observation that HDL 
induce PTX3 expression in ECs, an effect mainly dependent on apolipoprotein AI 
(apoAI) [42, 95]; furthermore, PTX3 could favor the clearance of lipid-loaded 
macrophages and VSMCs apoptotic cells mediating their removal by mature DCs, 
but, at the same time, oxidized LDL (but not native LDL) increases PTX3 mRNA 
expression in vascular SMCs (VSMCs), an effect dependent on NF-κB activation 
[35]. 
Ischemic Diseases 
Plasma concentration of PTX3 rapidly rises in the early phase after ischemic heart 
disorders in humans and animal models [41, 60, 86, 96] suggesting the possibility 
that PTX3 could also play a role in myocardial infarction. In experimental models of  
myocardial infarction (coronary artery ligation and reperfusion) an increased PTX3 
mRNA and protein expression was observed in the ischemic area of the heart; 
however, PTX3 KO mice had greater myocardial lesions, an increased tissue damage 
with a greater no-reflow area, increased neutrophils and macrophage infiltration, 
decreased number of capillaries, and increased number of apoptotic cardiomyocytes, 
a phenotype reversed by the use of exogenous PTX3 [41]. The protective effect of 
PTX3 was referred to a dampening of an excessive complement system activation: 
indeed, C3 deposition was increased in infarct areas of PTX3 KO mice compared to 
WT [41]. In agreement with the latter findings, a recent study revealed a crucial role 
for PTX3 in cardiomyocyte ischemia reperfusion (I/R) injury: PTX3 ameliorated 
cardiomyocyte apoptosis and infiltration of neutrophils and macrophages and then 
improved hemodynamic performance; this was associated with restricted expansion 
of γδ T cell and decreased expression of IL-6 and IL-23/IL-17A [97]. Of note, the 
protective role of PTX3 during I/R injury was depended on the protein produced by 
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bone marrow (BM)-derived cells, which inhibited infiltration of neutrophils and ROS 
generation at the ischemic myocardium, thereby resulting in the reduction of infarct 
size [98]. After 6 days from an ischemic brain injury, PTX3 KO mice presented a 
higher blood–brain barrier (BBB) damage and an impaired edema resolution 
compared to WT, while at early time point (48 h) no differences were observed in 
infarct volume, brain edema and blood–brain barrier (BBB) damage [99]. 
However, other works highlighted different roles played by PTX3: in an intestinal 
ischemia/reperfusion model, obtained by the total occlusion of the superior 
mesenteric artery, PTX3 overexpression was associated with increased cytokines 
production, tissue inflammation, and a reduced survival [100], a finding later 
confirmed in PTX3 KO mice which showed an opposite profile [101]. Instead, a 
reversible effect was reported in ischemic acute kidney injury (AKI): PTX3 KO mice 
was shown to have a reduced early expression of endothelial adhesion molecules and 
chemokines, and an ameliorated acute kidney injury [102]; however, other reports 
showed that the post-ischemic renal injury was aggravated in PTX3 KO mice [103], 
and PTX3 administration was able to prevent renal leukocyte recruitment and post-
ischemic kidney injury.  
These works clearly reveal that the molecule may have different functions in 
different settings or temporal windows of pathophysiological conditions. 
Neutrophils recruitment: PTX3/P-selectin interaction 
Neutrophils recruitment and infiltration into tissues is a common hallmark observed 
during the inflammatory/infectious response, where they can act as a double-edged 
sword, participating in tissue repair and defense but also further promoting tissue 
damage, as observed in ischemia-reperfusion injury. 
During inflammation, flowing neutrophils tether to and roll on vascular surfaces by 
reversible binding of P-, L- and E-selectin to glycosylated ligands [104, 105]; P-
selectin is rapidly mobilizes from secretory granules to the surfaces of endothelial 
cells and platelets after activation by thrombin, complement and other mediators and  
initiates rolling by interacting with the transmembrane mucin PSGL-1 on neutrophils 
[106]. Mantovani and colleagues demonstrated that PTX3, either derived from 
Introduction 
19 
 
activated leukocytes or administered exogenously, through the interaction with P-
selectin, could attenuate neutrophils recruitment at sites of inflammation in a model 
of pleurisy or acute lung injury, thus dampening inflammatory response [57]. The 
inhibition of neutrophils rolling on P-selectin arose the possibility that this 
mechanism could have also been relevant in disorders where an excessive neutrophil 
recruitment to activated endothelium and collateral damages associated to leukocyte 
activation, such as acute coronary syndromes, could play a role [107].  
PTX3, stored in neutrophils' secondary granules, was identified as the source of 
circulating protein, whose plasma levels dramatically increased after early acute 
myocardial infarction (AMI): the depletion of neutrophils intracellular PTX3 was 
associated with decreased platelets-neutrophils aggregates and with the binding 
between PTX3 and activated platelets, which dampens their inflammatory potential 
and pro-thrombotic effect [108].  
PTX3 and cancer 
Inflammation is a constant feature of tumors. The tumor microenvironment (TME) is 
rich in inflammatory cells and inflammatory mediators that strongly affect tumor 
growth and progression as well as metastatic spreading. Therefore the involvement 
of PTX3 in the pathogenesis of cancer has been widely investigated.   
Increased levels of PTX3 have been associated with cancer: PTX3 was identified by 
proteomic approaches as an important candidate biomarker for prostate cancer [109], 
lung cancer [110], liposarcomas [111] and more recently pancreatic carcinoma [112]. 
However, the role of PTX3 in cancer progression remains unknown. Molecular 
studies indicated that PTX3 exerts an anti-tumoral activity in prostate cancer by 
inhibiting FGF2/FGF8b-dependent angiogenesis [73, 113], and through autocrine 
and paracrine activities on cancer cells that may contribute to tumor progression 
[114]. The overexpression of the PTX3 N-terminal domain, which binds to FGF2 
[74], strongly inhibits the tumorigenic activity of TRAMP (Transgenic 
Adenocarcinoma Mouse Prostate)-C2 transfectants, whereas overexpression of the 
C-terminus has only a minor effect on tumor growth [113]. Although, PTX3 
expression appears to be significantly down-regulated in various human prostate 
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cancer datasets [115], more recently a strong correlation between the expression of 
pentraxin family members and prognosis of pancreatic carcinoma was found [112], 
thus proposing pentraxins, especially PTX3, as promising biomarkers in the 
prognosis of pancreatic carcinoma patients, whose plasma levels positively 
correlated with other pro-inflammatory markers as CRP, interleukin-6 and 
macrophage-inhibitory factor. Furthermore, it was shown that PTX3 is secreted by 
several pancreatic carcinoma cell lines [112]. 
However, contrasting results were obtained in experimental models: PTX3 was both 
associated with tumor progression, by preventing the phagocytosis of tumor cells 
induced by tumor associated macrophages (TAM) in nasopharyngeal carcinoma 
[116], but also with a pivotal role in controlling tumor growth, related to its ability to 
modulate the inflammatory response [117]: PTX3 deficiency was indeed associated 
with increased susceptibility to mesenchymal and epithelial carcinogenesis. 
Increased susceptibility of PTX3 KO mice was associated with enhanced tumor-
promoting macrophage infiltration, CCL2 production and angiogenesis. Furthermore, 
in the same paper, PTX3 expression was found to be epigenetically regulated in 
selected human tumors (leiomyosarcomas and colorectal cancer) by methylation of 
the promoter region and of a putative enhancer, concluding that PTX3, an effector 
molecule belonging to the humoral arm of innate immunity, acts as an extrinsic 
oncosuppressor gene in mouse and man by regulating complement-dependent, 
macrophage-sustained, tumor-promoting inflammation [117]. 
PTX3 and metabolic diseases  
The role of PTX3 in metabolic diseases has been investigated so far with 
associational studies in obese subjects; however, a protective or detrimental effect in 
these pathological conditions has not been clearly identify. 
PTX3 production by adipocytes was first proved by the transient expression of the 
protein in the early 3T3-F442A preadipocytes [34], a finding linked to the 
macrophage-like functions of preadipocytes, consistent with the involvement of 
adipose tissue in immune response during inflammation [118]. Despite the fact that 
PTX3 expression and secretion becomes low, if any, in mature adipocytes, its 
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expression and secretion were dramatically induced in vitro during TNFα exposure 
[118]. Furthermore, genetically obese and diabetic obese mice (ob/ob and db/db) 
presented an increased mRNA PTX3 expression in epididymal fat pads compared to 
lean mice [118] and some evidence reported an increased levels of PTX3 plasma 
levels in obese mice. Similarly, in humans PTX3 is expressed by preadipocytes and 
mature adipocytes in visceral (VAT) and subcutaneous adipose tissue (SCAT) and is 
directly related to TNFα expression in the VAT only; furthermore PTX3 expression 
has been associated with obesity and with several cardiovascular risk factors [119]. 
However, over all data from human studies are contradictory suggesting that plasma 
PTX3 protein levels are both elevated in obese individuals [120], associated with 
increased visceral adipose tissue expression and a cardiovascular risk profile [119], 
and in individuals with a metabolic syndrome phenotype [121]; but also inversely 
related with body mass index [122-126]. In detail, Zanetti and colleagues showed a 
novel association between PTX3 and atherogenic lipid profile: PTX3 levels were 
higher in subjects with low HDL, a strong predictor of cardiovascular disease both in 
the general and metabolic syndrome population [127, 128] which it is implicated in 
the progression of carotid artery intima-media thickening in the syndrome [129], and 
directly correlated with elevated triglycerides and intimal media thickness (IMT) 
[121]. However, in another study, a negative correlation was found between plasma 
PTX3 and insulin secretion after both intravenous and oral glucose administration 
and with obesity indexes, specifically body weight and waist circumference [122]. 
These contrasting findings might be in line with different functions of PTX3 during 
obesity, as reported in other pathological contexts, at the paracrine/autocrine levels in 
adipose tissue or at the systemic level: PTX3 is indeed expressed in different tissues 
and cell types, therefore, further work will be necessary to ascertain the contribution 
of each of the tissues/cells characterized by an high-expression of PTX3 to plasma 
protein levels and a possible differential regulation.  
PTX3 as a biomarker of human cardiometabolic diseases 
The observation that PTX3, in contrast to the liver-produced CRP, is produced by 
different cell types suggests that it may represent a rapid marker reflecting the local 
Introduction 
22 
 
activation of innate immunity and inflammation. Indeed, the general characteristics 
emerging from studies on PTX3 blood levels in human pathologies are the rapidity of 
its increase as compared with CRP, consistent with the identification of PTX3 as an 
early induced gene, the correlation with the severity of the disease, and the lack of 
correlation between levels of CRP and PTX3 [71]. Increased levels of PTX3 have 
been associated with different pathological conditions, from cardiometabolic to 
autoimmune diseases. In a restricted set of autoimmune disorders, as the small-vessel 
vasculitis, PTX3 levels, derived from ECs [130], correlate with clinical activity of 
the disease and represent a candidate marker for monitoring the disease [131]. 
Pregnancy itself, a condition associated with relevant involvement of inflammatory 
molecules at the implantation site [132], is associated with slight increase in maternal 
circulating PTX3 levels compared with the non-pregnant condition. Higher maternal 
PTX3 levels were observed in pregnancies complicated by preeclampsia [133, 134], 
which represents the clinical manifestation of an endothelial dysfunction as part of an 
excessive maternal inflammatory response to pregnancy [133, 135, 136].  
Because of the homology between PTX3 and CRP, the relevance of PTX3 
measurement as diagnostic tool has been investigated in cardiovascular pathology: 
following myocardial infarction (MI), PTX3 plasma levels peak within 7.5 hours as 
compared to CRP which peaks around 50 hours [60]. In MI patients, PTX3 but not 
CRP, after adjustment for major risk factors and other acute phase proteins, 
independently predicted 3-month mortality [96], thus suggesting PTX3 as a strong 
prognostic marker of CVD death, independently of other acute phase proteins. 
In the Bruneck study, PTX3 plasma levels, although not correlated with carotid 
artery IMT, were higher in individuals with atherosclerotic plaques and prevalent 
vascular diseases [137].  
PTX3 is present in the intact myocardium, increases in the blood of patients with 
acute myocardial infarction, and represent an early indicator of myocytes irreversible 
injury in ischemic cardiomyopathy [60]. In a large cohort of patients with myocardial 
infarction, with ST elevation, PTX3 but not the liver-derived short pentraxin CRP or 
other cardiac biomarkers (NT-proBNP, TnT, CK) predicted 3-month mortality after 
adjustment for major risk factors and other acute-phase prognostic markers [96]. A 
Introduction 
23 
 
similar observation was confirmed in the Cardiovascular Health Study where PTX3 
was showed to be independently associated with increased risk of all-cause death and 
cardiovascular-disease-(CVD) related mortality (also after adjusting for all major 
cardio-metabolic risk factors) [138]. Further studies confirmed that PTX3 represents 
a more specific marker for acute coronary syndrome (ACS) compared to neutrophils 
activating peptide-2 (NAP-2) and cardiac troponin I (cTnI) in patients with unstable 
angina pectoris, NSTEMI, and STEMI within the first six hours of the onset of chest 
pain [139]. These findings support the concept of PTX3 as a very sensitive marker of 
plaque inflammation and vulnerability and of the prognosis of the coronary disease. 
Patients with unstable angina pectoris and those who undergo percutaneous coronary 
intervention generally present PTX3 levels three times higher than the reference 
range [140]. Coronary stenting enhances circulating PTX3 levels in association with 
an inflammatory response and the levels are positively correlated with the increase in 
activated Mac-1 on the surface of neutrophils at 48 h in the coronary sinus [141]. 
These data suggest that PTX3 may be a useful marker for evaluation of inflammatory 
reaction and neointimal thickening after coronary vascular injury and also 
myocardial infarction. 
Among the different markers of inflammation tested, PTX3 was consistently 
associated with outcomes in heart failure (HF) patients [142]. In two large 
independent clinical trials (CORONA and GISSI-HF), baseline elevated PTX3 was 
associated with a higher risk of all-cause mortality, cardiovascular mortality or 
hospitalization for worsening HF [142]. PTX3 levels were positively associated with 
the severity of dilatative cardiomyopathy and increased risk of HF [143]. 
Furthermore high PTX3 plasma levels (but not CRP, interleukin-6, or TNF-α) were 
associated with an echocardiographic measure of left ventricular dysfunction (E/e′ 
ratio) in controls without HF and in patients with HF and normal or reduced ejection 
fraction [144]. These findings would suggest that in humans PTX3 could be either a 
bystander resulting from the action of pro-inflammatory cytokines in damaged 
tissues or a molecule directly involved in the extent and outcome of the inflammatory 
response.  
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PTX3 and genetic variants 
More informative data of the role of PTX3 in humans came from the analysis of 
single-nucleotide polymorphisms (SNPs) in the PTX3 gene: PTX3 SNPs have been 
shown to modify the risk of pulmonary tuberculosis [145] and colonization by 
Pseudomonas aeruginosa in patients with cystic fibrosis [146]. Furthermore, these 
SNPs were found to alter blood levels of the PTX3 protein in Ghanaian women [147] 
and in lung-transplant recipients with primary graft dysfunction [148]. In another 
study, three common PTX3 polymorphisms (rs2305619, rs3816527 and rs1840680) 
were found not to significantly influence the risk of acute myocardial infarction 
(AMI) in an European population, even if these SNPs, and the corresponding 
haplotypes, are associated with different levels of PTX3 in the blood; the most 
frequent haplotype, GAG, associated with lower plasma PTX3 levels than ACA and 
AAA. Conceivably haplotypes affecting PTX3 levels are not relevant for the risk of 
AMI, although the authors confirmed the prognostic value of PTX3 plasma levels in 
AMI patients [149]. The G-A/G-A haplotype was consistently associated with a 
defect in PTX3 expression in bronchoalveolar-lavage fluid, lung-biopsy specimens, 
and innate immune cells; the decreased expression of PTX3 transcript in neutrophil 
precursors was consistent with the predicted alterations in the mRNA secondary 
structure, which likely affects regulation of PTX3 expression. Clinically, genetic 
deficiency of PTX3 affects the antifungal function of neutrophils, increasing the 
susceptibility to invasive aspergillosis in patients undergoing hematopoietic stem cell 
transplantation [150].  
Another PTX3 polymorphism (rs2305619, A/A genotype) was associated with high 
levels of PTX3 and with hepatocellular carcinoma (HCC) in individuals chronically 
infected by hepatitis C virus (HCV); in a multivariate analysis, adjusting potential 
confounding factors, patients carrying the A/A genotype had almost two times more 
chance to have HCC [151]. 
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Physiopathology of arterial thrombosis 
Clinical manifestation of arterial thrombosis 
Arterial thrombosis is usually defined as the formation of a thrombus in an arterial 
vessel. In most cases, arterial thrombosis follows rupture of atheroma, and is 
therefore referred as atherothrombosis, the leading cause of mortality in the 
industrialized world (Figure 4). Atherosclerosis is a diffuse process that starts early 
in childhood and progresses asymptomatically through adult life. Later in life, it is 
clinically manifested as coronary artery disease (CAD), stroke, transient ischemic 
attack (TIA), and peripheral arterial disease (PAD) [152].  
The earliest pathologic process of atherothrombosis is endothelial dysfunction, a 
systemic, reversible disorder [153], which results in the recruitment of inflammatory 
cells into the vessel wall and in the initiation of atherosclerosis [154]. Endothelial 
cells produce cytokines, express adhesion molecules such as ICAM-1, VCAM, and 
selectins, and assist leukocytes and other blood-derived cells in “homing” and 
atheroma infiltration. Although fatty streaks have been found to be present already in 
the intima of infants [155], in advanced disease stages, secondary changes may occur 
in the underlying media and adventitia, leading to the progression of lesions to 
fibroatheroma by developing a cap of smooth muscle cells and collagen. 
Atherosclerotic lesions can progress without compromising the lumen because of 
compensatory vascular enlargement (positive remodelling) [156], which 
characterizes lipid-rich lesions; plaque disruption and subsequent thrombus 
formation is responsible for the onset of most acute coronary syndromes (ACSs) and 
strokes. The magnitude of the thrombotic process triggered upon plaque disruption is 
modulated by different elements that determine plaque and blood thrombogenicity: 
local shear rate, tissue factor (TF), apoptotic microparticles, circulating monocytes, 
and others [152].  
The major risk factors for the development of atherothrombotic diseases include 
smoking, diabetes, hypertension, obesity, physical inactivity, advancing age, positive 
family history, low high-density lipoprotein cholesterol level, and high low-density 
lipoprotein cholesterol level, while emerging risk factors comprise elevated levels of 
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triglycerides, small low-density lipoprotein particles, lipoprotein(a) and coagulation 
factors (plasminogen activating factor inhibitor 1 and fibrinogen) [157]. Treatment of 
atherothrombotic patients must include the management of modifiable risk factors 
through lifestyle changes, and antiplatelet treatment for the prevention of thrombotic 
complications. The aims of antiplatelet therapy are, firstly, to prevent the occurrence 
of acute ischemic events through inhibition of platelet thrombus formation and, 
secondly, to protect distal tissues by inhibiting microembolisation [152]. Despite the 
important beneficial effect of antiplatelet therapy in atherothrombotic disease, the 
mortality of this pathology is still high, therefore novel antithrombotic agents have 
been developed, as agents inhibiting the tissue factor metabolic pathway [152]; 
however, innovative therapies are warranted. 
Hemostasis and blood coagulation 
Thrombus formation at sites of vascular injury is crucial for normal hemostasis, but it 
also leads to arterial thrombosis in pathological conditions. The blood coagulation 
system comprises platelet adhesion, activation and aggregation, fibrin formation, and 
fibrinolysis. Activation of blood coagulation occurs primary through interaction 
between platelets, vessel wall and plasma proteins (primary haemostasis). When the 
endothelial layer is damaged and possibly disrupted as a consequence of the injury to 
blood vessel wall, the underlying extracellular matrix is exposed and triggers sudden 
platelet activation and adhesion [158]. Initial platelet adhesion to the damaged vessel 
wall is mainly mediated through interaction of the platelet GPIb–V–IX receptor 
complex with Von Willebrand factor (vWF) bound to exposed collagen [159]. After 
adhesion of the platelets, they become deformed due to cytoskeletal changes, thereby 
exposing activated integrins and releasing dense granule contents (ADP and ATP) 
and serotonin. Later, platelets secrete fibrinogen, fibronectin and vWF, stored in the 
alpha granules, expose fibrinogen and fibronectin receptors and P-selectin on their 
surface, and finally release lipid products [160], as the arachidonic acid, which is 
converted to thromboxane A2, a powerful mediator of platelet aggregating response. 
These phenomena lead to the “final common pathway” of platelet activation, the 
functional upregulation of integrin adhesion receptors, stable adhesion on the ECM 
and platelet aggregation. Among the integrins expressed by platelets, αIIbβIII is 
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considered the most important as it mediates adhesion to the subendothelium [161] 
and platelet aggregation by binding of fibrinogen [158]. Activated platelets also 
contribute to coagulation by exposing phosphatidylserine (PS) which enhances the 
assembly and activity of two major coagulation factor complexes on the platelet 
surface. Indeed, to insure stability of the initially platelet aggregate (platelet plug), a 
fibrin mesh (also called the clot) forms and entraps the plug by the activation of the 
coagulation cascade. If the clot contains only platelets it is called a white thrombus; 
if red blood cells are present it is called a red thrombus. The coagulation cascade, 
also known as secondary hemostasis, consists of the stepwise activation of inactive 
precursors (zymogens) leading to the formation of the ultimate product of fibrin. The 
coagulation cascade includes the intrinsic pathway (dependent on contact activation 
by a negatively-charged surface, and involving coagulation factors XII, XI, IX, VIII 
and V), and the extrinsic pathway (dependent on tissue-factor being exposed to the 
circulation, and involving tissue factor and factor VII), converging on a common 
pathway to activate factor X, leading to conversion of prothrombin (factor II) to 
thrombin (factor IIa) and culminating in the conversion of fibrinogen to fibrin [162].  
In the extrinsic pathway, circulating factor VII is activated to VIIa (FVIIa) and form 
a complex with exposed tissue factor (TF-FVIIA); FVIIa directly activates factor IX 
and X. In the intrinsic pathway, high-molecular-weight kininogen (HMWK), 
prekallikrein, and factor XII (Hageman factor) generates a complex with exposed 
collagen. Prekallikrein is converted to kallikrein and factor XII becomes factor XIIa. 
Both the intrinsic and extrinsic use the common pathway which start with the 
activation of FXa. FXa generates the “pro-thrombin complex” with FV, platelet 
factors and Ca
2+
, to activate FII to thrombin; thrombin cleaves fibrinogen in soluble 
fibrin, which thanks to FXIII becomes insoluble and bridges the initial platelet 
aggregate to form a stable clot. Finally, physiologically, the clot must be dissolved to 
resume normal blood flow following tissue repair, a process known as fibrinolysis. 
The dissolution of the clot occurs through the action of plasmin, a protease which is 
generated from circulating plasminogen by FXIIa [162].  
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P-selectin 
P-selectin is an integral membrane protein, belonging to the selectins, a family of 
adhesion molecules, expressed on the surface of both platelet and endothelial cells. It 
is stored in platelet α granules and in Weibel-Palade bodies of endothelial cells [163]. 
P-selectin is involved in a number of processes, including platelet aggregation, 
platelet-endothelium and platelet-leukocyte interactions [164].  
After degranulation, P-selectin rapidly translocates on plasma membrane where it 
mediates the stabilization of platelet aggregates and leukocyte rolling, the first step of 
cellular adhesion [163, 165, 166], which is crucial during inflammation and 
leukocyte recruitment at the injured site [164].  
Furthermore, P-selectin is a key player for platelet and leukocyte interactions as 
platelet P-selectin binds PSGL-1 (P-selectin glycoprotein ligand 1), expressed on 
leukocyte surface, leading to aggregates formation which induce the release of 
chemokines as CCL2 and CCL5, cytokines as IL-1β responsible of the propagation 
of the inflammatory response [167, 168]. The relevance of this interaction has been 
proved in P-selectin KO [169] and PSGL1 KO mice [170], which show a 
dramatically reduced leukocyte rolling. Platelet-leukocyte rolling is a typical feature 
of inflammatory states as well as cardiovascular diseases [171-177] and the adhesion 
and following rolling of platelet-leukocyte aggregates is significantly stronger than 
those of single leukocytes [178]. Indeed, P-selectin KO mice exhibited a significant 
prolongation of time to thrombotic occlusion after arterial injury and decreased 
platelet-leukocyte aggregates [179]. Therefore, platelet-derived P-selectin has a key 
role during arterial thrombosis, enhancing stable interactions between platelets and 
leukocytes [179], and inducing the release of endothelial-derived P-selectin, thus 
resulting in leukocyte rolling on activated endothelium [167]. Furthermore, platelet-
derived P-selectin contributes to atherogenesis promoting platelet-leukocyte and 
monocytes aggregates [180], increasing leukocyte adhesion on ECs and macrophage 
recruitment in the arterial wall [181]. Indeed, in mouse models of atherosclerosis 
(apoE KO mice), P-selectin deficiency is associated with a significantly reduction of 
atherosclerotic lesion and leukocyte recruitment [182]. 
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Role of extracellular matrix proteins in the thrombotic event 
The interactions between platelets and extracellular matrix (ECM) proteins, derived 
from the vessel wall, plasma, platelets themselves, are central to both the initial 
adhesion and the subsequent activation and aggregation of platelets, which, together 
with coagulation, generate the fibrin clot [158]. ECM proteins are actively synthesize 
by endothelial cells, which deposit them basally or retain them in the Weibel-Palade 
bodies; under the endothelial cell layer, the basement membrane contains type IV 
collagen, laminins, nidogens, and perlecan [183]. Below ECs, smooth muscle cells, 
in larger vessels, form a separate medial layer with its own extracellular matrix 
components including elastin and collagens [184]. Therefore, the ECM proteins to 
which platelets and leukocytes become exposed depend on the degree of injury to the 
vessels: mild injuries, as the damage to the endothelial layer, will expose type IV 
collagen, laminins, and VWF, whereas more extensive injuries exposing the smooth 
muscle layer or interstitial ECM will expose them in addition to fibrillar collagens, 
elastin and other ECM proteins [185]. 
Platelet adhesion under arterial high shear conditions (as in arteries) is a multistep 
process that requires interaction of various receptors, some generic and some 
platelet-specific, with their ligands in the ECM [158]. One of the best characterize 
ECM receptor is the integrin, αIIbβIII, which exhibits a tightly regulated switch 
between inactive and active states. Once activated, αIIbβIII binds many different 
ECM proteins, particularly fibrinogen, its major ligand, leading to platelet 
aggregation and formation of an occlusive thrombus [185]. Fibrillar collagens are 
potent activators of GPVI and are thus considered strong triggers of thrombosis. 
However, while fibrillar collagens type I, III, and V are found in the deeper layers of 
the ECM and are thus not accessible after superficial injury, collagens type IV, VIII, 
and XVIII are expressed in the basement membrane and studies on experimental 
models of thrombosis have demonstrated that even type IV collagen can trigger 
GPVI-dependent thrombosis induced by superficial injury to the vessel wall [186]. 
Collagen receptors: GPVI and α2β1 
Collagen consists of GXY sequences (G glycine, X and Y are often proline and 
hydroxyproline). Barnes and Farndale showed that 10% of collagen type I and III is 
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constituted by GPO sequence (where O is hydroxyproline), which is the strongest 
stimulus of platelet activation through its interaction with GPVI [187]; they also 
demonstrated that another specialized sequence, the GFOGER, is recognized and 
bound by integrin α2β1 [188, 189]. The role of these receptors in platelet adhesion to 
collagen is highly debated: GPVI is essential for platelet activation and aggregation 
to collagen, while integrin α2β1 contributes to the firmly adhesion of platelets on 
exposed collagen [190].  
GPVI is a component of immunoglobulin superfamily and its activity depends on the 
interaction with Fcγ (Fc receptor γ subunit). GPVI presents a ITAM sequence 
(immunoreceptor tyrosine-based activation motif), which, together with the adaptor 
proteins LAT e LCP2 and the tirosyn kinase SYK, activates PLCγ2 (phospholipase 
Cγ2), leading to the production of the second messengers DAG (1,2-diacylglycerol) 
and IP3 (inositol 1,4,5-trisphosphate). DAG activates PKC (protein kinase C), while 
IP3 promotes Ca
2+
 release from intracellular storage, increasing its cytosolic 
concentration. GPVI-mediated activation induces integrin exposure, release of 
intracellular mediators, thus playing a key role in thrombus formation [190, 191]. 
Integrins are heterodimeric receptors, with a big subunit α and a small one β, which 
controls the interaction with ECM proteins and between cells, contributing to a 
variety of biological processes [192]. Integrins are usually expressed in a low affinity 
state, which switches to an high affinity state after platelet activation, a process 
known as “inside-out” signaling. On the other way, integrin ligands can trigger other 
cellular processes, as the spreading on the exposed ECM proteins, with the “outside-
in” signaling [193]. Integrin α2β1 has been shown to bind collagen type I, II, III, IV 
and XI, however its role in the haemostasis and thrombosis is still debated: α2β1 has 
an important, but not essential role in platelet adhesion together with other integrins, 
as  αIIbβIII [194, 195]. Furthermore, the “inside-out” signaling, triggered by GPVI, 
regulates α2β1 expression and, at the same time, the interaction between collagen 
and α2β1 induces an intracellular activation, similar to that of GPVI (activation of 
PLCγ2) [190]. 
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Experimental models of arterial thrombosis 
The study of blood coagulation has been experimentally achieved by the knocking-
out or over-expression of its components; in addition, numerous genes encoding 
platelet, vascular endothelial cell, and vascular smooth muscle cell proteins have 
been targeted in animal models, especially mice. These genetically modified animals 
have provided tremendous opportunities to examine the functions of specific genes in 
vivo and their roles in disease processes, to test the effect of different compounds 
affecting blood coagulation. Beyond these approaches, a variety of murine 
thrombosis models, which mimic human vascular diseases, have been developed to 
investigate blood coagulation, and directly visualize platelet-platelet and platelet-
endothelium interactions [186, 196, 197].  The most used models, which generally 
induce lesions in different vascular beds usually by chemical injury, include the 
external application of ferric chloride (FeCl3) [198, 199], injection of Rose Bengal 
followed by light excitation [200], or mechanical injury through arterial 
compression, ligation or introduction of a guide wire [201, 202]. 
Ferric chloride (FeCl3) injury 
FeCl3 injury consists in the direct application of a filter paper saturated with a 
solution of ferric chloride (usually from 5% to 50%) to the adventitial surface of an 
artery which rapidly induces formation of a platelet-rich thrombus that typically 
progresses to complete vascular occlusion within 20 - 40 minutes [199]. A 
microvascular probe is used to monitor blood flow within the artery. The degree of 
arterial thrombosis depends on the concentration of FeCl3 solution, the size of filter 
paper and the time of application (generally from 1 to 3 minutes); however, thrombi 
that form in mice after FeCl3 injury are platelet-rich and exhibit a microscopic 
appearance that is very similar to that of arterial thrombi that form in humans [203]. 
The exact mechanism by which thrombus formation is triggered in this model has not 
been clear for many years. The FeCl3 injury, which has been described as “outside-
inside”, produces transmural cell necrosis and disrupts the integrity of the vascular 
endothelium. However, the precise mechanism by which ferric chloride triggers 
thrombosis is still debated: initially, clot initiation has been attributed to free iron-
induced denudation of endothelial cells and the subsequent exposure of the 
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subendothelium that triggers platelet adhesion/aggregation and activation of the 
coagulation cascade [201], but later, studies using mice deficient in collagen receptor 
GPVI have produced contradictory results, reporting both normal and altered 
thrombus formation [204, 205]. However, more recent works showed that after FeCl3 
application platelet adhesion occurs both on a denudated endothelial layer with a 
limited collagen exposure in the vessel [206], and on a intact endothelium mediated 
by erythrocytes as revealed with scanning electron microscope (SEM) analysis [207]. 
Indeed, another recent work showed that FeCl3 has multiple dose-dependent effects 
on blood, leading to a 2-phase mechanism of action: in the first phase, the charge-
based complexation of positively charged iron species and negatively charged 
proteins (cell surface bound and in solution) initiates FeCl3-induced thrombosis 
independent of biological ligand-receptor interactions. Erythrocytes are the first 
adherent blood component, and form the bulk of the initial aggregate. In the second 
phase, endothelial cell death and iron-bound, adherent blood components initiate the 
conventional biological clotting cascade [208]. 
Photochemical injury 
The photochemical injury involves intravenous administration of a photoreactive 
substance, usually Rose Bengal, followed by illumination of an exposed arterial 
segment with green light (540 nm) delivered from a xenon lamp equipped with a 
heat-absorbing filter [200, 209]. Rose Bengal accumulates in the membranes of 
endothelial and other cells [210], and the exposure to green light triggers locally a 
photochemical reaction that produces singlet oxygen and promotes the formation of 
other reactive oxygen species that damage the vascular endothelium and induce the 
formation of occlusive thrombi within 30 - 40 minutes [200, 209].  
More recently, lasers have been used to induce endothelial injury in the 
microcirculation [211], which typically triggers the formation of non-occluding 
thrombi within a few minutes; therefore, different type and severity of lesions can be 
achieved depending on the intensity and exposure time of the laser beam which may 
be useful to identify potentially different mechanisms of thrombus formation 
triggered by the exposure of different layers of the vessel wall [197]. 
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Mechanic injury 
Endothelial denudation can be induced mechanically in large arteries (aorta, carotid 
artery, femoral artery) either by direct damage of the luminal side of the vessel using 
a guide-wire [205, 212] or indirectly by compression or ligation of the vessel using a 
forceps or a filament [213, 214]. All these procedures result in the exposure of the 
native ECM thereby triggering thrombus formation by collagen- and thrombin-
dependent mechanisms which may perhaps best reflect naturally occurring vascular 
lesions [197].  
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Obesity and metabolic diseases 
Obesity and its metabolic complications (generally referred as metabolic syndrome, 
MetS) are a complex disease with high socio-economic cost and are considered a 
worldwide epidemic. MetS is associated with an increased risk of cardiovascular 
diseases [215], insulin resistance and type 2 diabetes [216], chronic kidney disease 
[217], risk of cancer [218] and pulmonary diseases [219]. 
Clinically, metabolic syndrome is defined as the presence of at least three of the 
following criteria: central obesity (waist circumference in men >102 cm and in 
women >88 cm), hypertriglyceridemia (≥150 mg/dL), low HDL cholesterol (men 
<40 mg/dL, women <50 mg/dL), elevated fasting glucose (>110 mg/dL), and 
hypertension (≥130/85 mmHg) [220]. A central feature is central obesity which 
predisposes to insulin resistance, resulting in hyperglycemia and hyperinsulinemia, 
and eventually leading to the development of diabetes [221]. Chronic inflammation 
is another feature of the metabolic syndrome, which, together with insulin resistance, 
results in complex metabolic derangements that contribute to the pathogenesis of 
hypertension, atherogenic lipoprotein profile, atherosclerosis, coronary artery 
disease, and other organ dysfunction [222, 223].  
The pathogenesis of obesity-associated diseases has revealed a close relationship 
between nutrient excess and derangements in the cellular and molecular mediators of 
immunity and inflammation, a phenomenon known as “metainflammation” [2] which 
describes the chronic low-grade inflammatory response to obesity. The inflammatory 
response triggered during obesity is attributed to the excess consumption of nutrients 
and therefore referred as metabolic. Furthermore, specialized metabolic cells (such as 
adipocytes) are the cells that sustain the insult and begin the inflammatory response, 
contributing to an unbalanced metabolic homeostasis [224]. Indeed, the finding in the 
1990s that tumor necrosis factor-alpha (TNFα) is overexpressed in the adipose tissue 
of obese mice provided the first clear link between obesity, diabetes and chronic 
inflammation [225]. This link between inflammation and metabolic dysfunction has 
also been proved in humans, as some pro-inflammatory markers have been positively 
correlated with the metabolic syndrome and insulin resistance [226-229]: obese 
subjects, indeed, present elevated white blood cell counts, plasma levels of 
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coagulation factors (fibrinogen and plasminogen activator inhibitor 1 (PAI-1)), 
acute-phase proteins such as C-reactive protein (CRP) and serum amyloid A (SAA), 
pro-inflammatory cytokines (TNFα, IL-1β and IL-6), and chemokines.  
Tissue inflammation in obesity 
Data from experimental and clinical studies have demonstrated that adipose tissue, 
liver, muscle and pancreas are sites of inflammation during obesity and insulin 
resistance. Particularly, macrophage infiltration into these tissue has been described 
as a key feature of obese-related inflammation in both humans and animal models of 
MetS. They act in an autocrine and paracrine manner releasing pro-inflammatory 
cytokines [230], including TNFα, IL-6 and IL-1β and by interfering with insulin 
signaling in peripheral tissues through activation of the c-JUN N-terminal kinase 
(JNK) and NF-κB pathways [231] (Figure 5). 
Adipose tissue 
The inflammatory response that emerges in the presence of obesity seems to be 
triggered by and to reside predominantly in adipose tissue, characterized by specific 
up-regulation of genes encoding inflammatory factors and an over-production of 
many cytokines and chemokines [232]. Adipose tissue has been associated with a 
marked accumulation in its stromovascular fraction of immune cells [230], 
particularly represented by macrophages, whose recruitment correlates with the 
degree of obesity and is crucial for the production of adipose tissue-derived pro-
inflammatory cytokines [233, 234]. However, enlarged adipocytes themselves are 
directly involved in the production of pro-inflammatory cytokines and chemokines 
[235]. In the adipose tissue of lean individuals, macrophages are usually polarized 
toward an M2, “alternatively activated” or “anti-inflammatory” subset, characterized 
by low pro-inflammatory but high anti-inflammatory cytokines (as IL-10 and IL-1 
decoy receptor) and arginase expression, which sustain the blockade of inflammatory 
responses and the promotion of tissue repair [236]. Therefore in adipose tissue, M2 
macrophages, derived from CCR2– monocytes, have a potential beneficial role, 
maintaining normal adipocyte function and perhaps by promoting tissue repair and 
angiogenesis in adipose tissue [237]. However, nutrient excess leading to adipocyte 
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expansion, is characterized by increased secretion of monocyte chemoattractants that 
recruit inflammatory type CCR2+ monocytes to fat, causing a phenotypic switch 
from M2 to M1, “classically activated” or “pro-inflammatory” macrophages. M1 
infiltration is directly correlated with adiposity, insulin resistance and adipose tissue 
inflammation. This tight relationship between obesity and inflammatory 
macrophages is confirmed by the observation that weight loss induced by surgery 
[238] or diet and exercise [239] results in a reduction in the number of adipose tissue 
macrophages in parallel to the decreased expression of pro-inflammatory markers in 
both adipose tissue and plasma of obese individuals. Although macrophages are the 
most abundant leukocyte population in expanding adipose tissue, other cells 
participate to the inflammatory response as neutrophils [240], mast cells [241], and 
natural killer T (NKT) [242]. Furthermore, the adaptive immune system may also 
contribute to obesity-induced inflammation: obesity is indeed associated with 
changes in the adipose tissue T cell populations, with an increased ratio of CD8+ and 
CD4+ T cells, especially of the effector phenotype, and decreased of the 
immunosuppressive T regulatory cells (Tregs), creating an environment favorable to 
immune activation [243-245] (Figure 6).  
Among the different fat depots, the intra-abdominal visceral fat is the key component 
of metabolic syndrome and is indirectly measured by waist circumference in clinical 
practice. Therefore, besides total adiposity, the pathogenic role of adipose tissue 
seems to be determined by its specific anatomic location: although both 
subcutaneous and visceral adipose tissues are associated with metabolic risk profile, 
visceral adiposity is the most important predisposing factor to metabolic syndrome 
[246], positively associated with ectopic lipid accumulation in liver and skeletal 
muscle, further sustaining insulin resistance and metabolic complications [247]. This 
different clinical significance is determined by different phenotypic, physiological 
and functional characteristics of visceral adipose tissue [247]: obese subjects have an 
evident pro-inflammatory profile more in the visceral compared to subcutaneous 
adipose tissue.  
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Liver 
The liver represents one of the major metabolic organ as it is involved in the control 
of gluconeogenesis, represent a glycogen storage, and it also contributes to 
lipogenesis, cholesterol synthesis and secretion [224]. Visceral obesity is often 
associated with nonalcoholic fatty liver disease (NAFLD), and its prevalence 
increases in parallel to that of type 2 diabetes (T2DM). NAFLD is one of the causes 
of fatty liver and includes a large spectrum of lesions, from simple steatosis to 
steatohepatitis (nonalcoholic steatohepatitis or NASH), which can lead to cirrhosis 
and hepatocarcinoma [248]. Similar to adipose tissue, inflammatory response has a 
pivotal role in the progression of the disease: NAFLD and subsequent hepatic insulin 
resistance in obesity are associated with increased expression and overproduction of 
inflammatory mediators, including TNFα, IL-6 and IL-1β [249]; however, unlike 
adipose tissue, the number of resident macrophages, which in the liver are known as 
Kupffer cells and represent the 10% of total liver cells, does not change but their 
activation status increased [249, 250]. Kupffer cells directly contribute to the 
production of pro-inflammatory mediators, sustaining insulin resistance in the liver 
[249, 250], which is associated with an increased level of circulating cytokines and 
acute-phase proteins as CRP, PAI-1, serum amyloid A, and IL-6 observed in obese 
animals and humans compared to lean controls [231, 251].  
Muscle 
The muscle is a key site of glucose uptake and energy consumption in the body, 
contributing to glucose homeostasis [224], and is another major site of insulin 
resistance during both obesity and type 2 diabetes. An infiltration of M1 
macrophages has been described in the skeletal muscle [252] and in the inter-
muscular adipose depots [233], associated with increased expression of inflammatory 
mediators, which contributes to locally insulin resistance and, indeed, gene 
expression of phenotype markers of pro- and anti-inflammatory macrophages in 
human skeletal muscle seems to correlate with insulin sensitivity [253]. However, 
muscle cells does not modulate inflammatory response during obesity or regulate 
metabolism through inflammatory kinase action; on the other hand, the influence of 
peripheral inflammation on muscle function is well established, as inflammatory 
cytokines are able to induce insulin resistance in muscle cells in culture [254, 255] 
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and in vivo by infusion into humans, resulting in decreased glucose uptake and 
glycogen synthesis [256]. 
Pancreas 
The pancreas is directly involved in the maintenance of glucose homeostasis, as the 
source of insulin and glucagon. Failure of this organ to produce sufficient insulin in 
response to rising systemic glucose levels is at the center of diabetic disease [224]. 
Type 1 diabetes is an established autoimmune disease where auto-reactive immune 
cells destroy the insulin-producing β cells, however, accumulating evidence suggest 
a central role of inflammatory response in the dysfunction of pancreas during type 2 
diabetes [224]. The insulin resistance, which is a key feature of obesity, is mainly 
related to a failure of pancreatic β cells to produce enough insulin to remove glucose 
from the circulation at normal concentration, leading to chronic hyperglycaemia. 
Therefore, an increased production of insulin, to compensate for its peripheral 
resistance, takes place, which is however associated with increased β cell stress and 
apoptosis. Indeed, an inflammatory response was demonstrated in the pancreatic 
islets of patients with type 2 diabetes as shown by the presence of amyloid deposits, 
fibrosis, increased β cell death and infiltration of macrophages along with increased 
levels of pro-inflammatory cytokines and chemokines [257], leading to immune cell 
recruitment in islets [258]. 
Animal models of obesity and MetS 
Animal models have been extensively used to study the mechanisms by which 
obesity induces pathological dysfunctions; among the types of animal models, 
rodents represent the most used model of obesity and its metabolic complications. 
However, before choosing an animal model is important to understand the basics of 
the controls of food intake and how they might relate to obesity. Factors that 
influence food intake and consequently body fat can be classified in those that have 
an influence when individuals start eating, those that influence when eating and at 
the end of eating: in detail, satiation factors interact in the brain with signals 
generating mainly from adipose tissue and pancreas, therefore representing a mirror 
of how lean or fat the individual is. These signals, such as leptin and insulin, interact 
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with receptors in the hypothalamus and have potent effects on food intake, energy 
expenditure and the level of stored fat. Most of the animal models commonly used to 
investigate causes and treatments for obesity have therefore altered activity in brain 
circuits integrating satiation and adiposity signals [259]. Based on these findings, 
animal models of obesity can be distinguished into different categories, depending on 
whether obesity derived from mutations or manipulations of genes involved in the 
energetic homeostasis (satiation and adiposity signals) or triggered by the 
consumption of high-fat diets in genetically intact animals. 
Genetically-induced obesity 
Animals with a defect in the leptin-signaling pathway in the hypothalamus of the 
brain develop an obese phenotype. Leptin is known as the "satiety hormone" [260], 
which is made by adipose cells and helps to regulate energy balance by inhibiting 
hunger. Leptin is opposed by the actions of the hormone ghrelin, the "hunger 
hormone". Both hormones act on receptors in the arcuate nucleus of the 
hypothalamus to regulate appetite and achieve energy homeostasis [261]. Obesity is 
usually characterized by a decreased sensitivity to leptin, resulting in an inability to 
detect satiety despite high energy stores [262]. The models with a defect in the 
leptin-signaling pathway include animals that lack leptin production and/or are 
insensitive to leptin due to leptin receptor mutations or extreme leptin resistance. 
Mutations are spontaneous (Lep
ob
/Lep
ob
 and Lep
db
/Lep
db
 mice) or genetically 
engineered. Lep
ob
/Lep
ob
 mice exhibit early-onset obesity characterized by 
hyperphagia, reduced energy expenditure and hypothermia; further defects are 
hypercorticosteronemia, insulin resistance associated with hyperglycemia and 
hyperinsulinemia, hypothyroidism and growth hormone deficiency leading to a 
decrease in linear growth [263-268]. The Lep
db
/Lep
db
 is phenotypically similar to the 
Lep
ob
/Lep
ob
, but their leptin levels are markedly elevated as a consequence of leptin 
receptor mutation; they are insulin resistant and develop diabetes [269]. 
Another monogenic spontaneous mutation affects the expression of aguti protein. 
Agouti is a pigment control gene transiently expressed in follicular melanocytes to 
induce the production of red/yellow pheomelanin pigment and inhibit black/brown 
pigment [270-272]. The lethal yellow mutant mouse (A
y
) is characterized by the 
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ubiquitous protein expression due to loss of the tissue-specific control promoter 
element [273, 274]. A
y
 mice exhibit several phenotypes such as a yellow coat color, 
mature-onset obesity, type-II diabetes, hyperleptinemia, increased linear growth, 
higher tumor susceptibility, and infertility [275]. 
Another monogenic mutation to mention is the melanocortin receptor 4 (MCR4) 
knock-out mice which is the model of the most frequent genetic cause of obesity in 
humans. MCR4 KO mice do not respond to leptin mice and are hyperinsulinemic, 
hyperglycemic and hyperleptinemic [276]. 
Beyond monogenic forms, other models of obesity include polygenic models which 
could be much more relevant to human obesity. 
Diet-induced obesity 
The diet-induced obese (DIO) rat and mouse offers more human-like models, where 
the obesity is based on several factors, including an excess intake of calories. 
However, diet-induced obesity in rodents can be obtained by different means; there is 
a large variation both with respect to the content of the diet used, as well as the strain 
used [277]. Among the various strains, C57BL/6J mice are the most widely used for 
high fat diet (HFD)-induced obesity because they exhibit abnormalities similar to 
human metabolic syndrome when fed the HFD [278]. The HFD usually used are 
composed by 45% or 60% of calories from fat as they are intended to mimic the 
western type diet. C57BL/6J exhibit an increase in body weight just after 2 weeks, 
but the increase is gradual and becomes apparent after 4 weeks. After 16–20 weeks 
of high-fat diet feeding, mouse will typically exhibit 20–30% increase in body 
weight when compared to chow-fed mouse [279]. The effects of HFD on blood 
glucose are more discrepant and depend on the type of dietary regimen. 
Hyperglycemia usually develops within 4 weeks of a high-fat diet [280]. The 
elevation of fasting glucose is usually accompanied by increases in fasting insulin 
levels and the hyperinsulinemic-euglycemic clamp experiments demonstrated whole-
body insulin resistance. Nevertheless, the full manifested picture of obesity develops 
after 16 weeks of high-fat diet with adipocyte hyperplasia, fat deposition in 
mesentery, increased fat mass, diabetes, and hypertension [281]. 
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Pentraxin 3 (PTX3) belongs to the pentraxin superfamily, soluble, multifunctional, 
pattern recognition proteins, and is an essential component of the humoral arm of 
innate immunity. More recently, it’s role in cardiometabolic diseases has gained 
attention thanks to the observation that, in humans, its plasma levels peak during 
cardiovascular diseases, while in mice PTX3 was shown to protect toward 
myocardial infarction, restenosis and atherosclerosis.  
Aim of this PhD project was to investigate the role of PTX3 in two common 
morbidities that affect particularly Western countries: arterial thrombosis, a critical 
complication of atherosclerotic plaque rupture correlated with clinical manifestations 
as myocardial infarction or stroke, obesity and its related metabolic complications, a 
worldwide epidemic with increasing socioeconomic cost.  
In vivo arterial thrombosis was characterized with the FeCl3-induced thrombosis in 
PTX3 KO and WT mice and in PTX3 KO chimera mice generated by bone marrow 
transplantation to reveal the source of the protein responsible for the phenotype 
observed. To study the relevance of the interaction between PTX3 and P-selectin, 
arterial thrombosis was characterized in PTX3/P-selectin double KO mice. Later the 
molecular mechanisms of the phenotype observed were investigated with in vivo and 
in vitro studies to selectively evaluate the contribution of platelets, leukocytes and 
vascular wall in FeCl3-induced arterial thrombosis. 
Metabolic syndrome and obesity was investigated feeding for 20 weeks PTX3 KO 
and WT mice to a high fat diet (HFD), characterized by 45% of calories from fat, 
which is a commonly used model of diet-induced obesity. Weight gain was measured 
weekly, while adipose tissue deposition in the visceral, subcutaneous and 
intrascapular area was checked after 10 and 20 weeks of diet. A characterization of 
gluco-metabolism was performed at 10 and 20 weeks of diet through test of gluco- 
and insulin tolerance. Finally, to evaluate possible molecular mechanisms, a 
characterization of the immune-inflammatory response of the visceral adipose tissue 
was carried out.  
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Animals 
PTX3 KO animals were generated at the Humanitas research institute as described in 
detail before [52]. Complete peripheral blood cell counts and microscopic 
examination of blood smears of PTX3 KO did not show statistically significant 
differences compared to WT animals. Microscopic examination of organs and tissues 
of young or adult mice (ten months old) did not reveal morphological abnormalities. 
Heterozygous females and males are normal and fertile and breeding yielded the 
predicted number of homozygous null mice at a mendelian frequency. However, 
PTX3 KO females exhibit a severe defect in fertility [52]. P-selectin KO mice were 
from the Jackson Laboratories and P-selectin/PTX3 KO mice were generated by 
crossing the two animal models. All mice were on a C57BL/6J background.  
The investigation conforms to the European Commission Directive 2010/63/EU and 
was approved by the Ethical Committee (Progetto di Ricerca 2009/3 and Progetto di 
Ricerca 2012/02). 
Bone marrow transplantation 
Wild-type (WT) or PTX3 KO mice were lethally irradiated with a total dose of 900 
cGy. Two hours later, mice were injected in the tail vein with 5 × 10
6
 nucleated bone 
marrow (BM) cells obtained by flushing of the cavity of a freshly dissected femur 
from a WT or PTX3 KO donor. Recipient mice received gentalyn (0.4 mg/ml in 
drinking water) starting 10 days before irradiation and maintained thereafter [57]. At 
8 weeks after BM transplantation, the FeCl3 injury model was carried out as 
described below. 
FeCl3 injury: experimental arterial thrombosis model 
Experimental arterial thrombosis was induced as originally described in the work of 
Kurz and colleagues [199]. Briefly, mice (8-12 week old) were anesthetized with 
ketamine chlorydrate (75 mg/Kg) and medetomidine (1 mg/Kg; Virbic). The left 
carotid artery was dissected free and placed in the probe (model 0.7V, Transonic 
System) connected to transonic flow meter (Transonic T106). After blood flow 
stabilization (baseline flow constant for 7 min), filter paper imbibed with FeCl3 (10-
20%) was applied downstream of the probe to the top of the exposed carotid. After 3 
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minutes, the filter paper was removed, the carotid artery was washed with PBS, and 
the flow was recorded for 30 minutes. In a group of experiments, human recombinant 
PTX3 (hPTX3, 5 mg/kg per mouse [57, 282]) or PBS (as negative control) was 
injected iv. before the arterial thrombosis experiment.  
Pulmonary thromboembolism 
A disseminated thrombosis model was generated in mice (8-12 week old) by i.v. 
injection of a mixture of collagen (0.45 mg/Kg) and epinephrine (0.055 mg/Kg); 
animals were monitored for 10 minutes. Death within this time frame was deemed to 
be a direct consequence of microthrombi formation in lung capillaries due to 
collagen/epinephrine administration. 
Platelet count, tail bleeding time and fibrinogen, PT and aPTT measurement 
Platelet were counted optically from whole blood collected by orbital sinus bleeding 
into Unopette System reservoirs. Bleeding time was measured on tails of 
anesthetized mice, and immersed in saline solution at 37°C. After 3 minutes the last 
part of the tail, 3 mm from its end, was cut with a sharp scalpel blade, then 
immediately re-immersed in saline solution. Bleeding was followed visually, and 
time was determined as the interval (sec) from the tail transection to cessation of 
bleeding; 900 sec was considered the cut off time for the purpose of statistical 
analysis [283, 284]. Fibrinogen levels were measured as previously described [285] 
from plasma (PPP) obtained after centrifugation of blood [collected by cardiac 
venipuncture from anesthetized mice into 3.8% sodium citrate (1:10 vol:vol)] at 1000 
g for 10 minutes. For prothrombin time (PT) test, PPP was mixed with Tissue Factor 
(TF) (containing phospholipid) at 37°C and an excess of calcium chloride (25 mM) 
was added to initiate coagulation. Time was determined as the interval (sec) between 
calcium addition and clot formation. For activated partial thromboplastin time 
(APTT) test, PPP was incubated at 37°C with phospholipid (cephalin) and a contact 
activator (e.g. Kaolin) was added followed by the calcium (all pre-warmed to 37°C). 
Addition of calcium initiates clotting and time was determined (sec) as the interval 
taken for a fibrin clot to form. 
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PTX3 plasma levels –ELISA assay 
PTX3 plasma levels were measured with a sandwich ELISA using 2 anti-murine 
PTX3 mAb (2C3 and 6B11) [42]. The ELISA assay did not cross-react with the short 
pentraxins CRP and SAP.  
P-selectin and integrin αIIbβIII expression on platelet surface 
Platelet rich plasma (PRP), isolated following centrifugation at 100xg with no break 
of  citrated blood, from PTX3 KO and WT mice was stimulated with collagen (10 
μg/mL, Mascia Brunelli, Italy) and U46619 (10 μM, Cayman Chemical, USA), an 
analogous of thromboxane for 1 or 10 minutes, for P-selectin or integrin αIIβIII, 
respectively, and then stained with the anti-CD42c FITC and anti-CD62P PE or 
αIIβIII PE antibodies (Emfret, Germany). Samples were fixed with PFA 4% and the 
expression of the platelet activation markers was evaluated through flow cytometry 
(BD FACS Calibur). 
Platelet-leukocyte aggregate analysis 
Citrated blood from PTX3 KO and WT mice was stimulated with ADP (40 μM, 
Sigma-Aldrich, Italy) for 30 seconds or 1 minute and fixed with BD lysis buffer; 
samples were stained with the anti-CD45 PE (BD) and anti-CD42c FITC antibodies 
(Emfret, Germany) and analyze through flow cytometry (BD FACS Calibur).  
Histology and immunofluorescence 
Mouse carotid arteries and lungs (perfused with PBS ) and adipose tissue were 
excised, fixed in 10% neutral formalin, processed and then embedded in paraffin. 
Section of 5 μm were stained with hematoxylin and eosin, or DAPI and fluorescent 
antibodies against PTX3 and fibrin and visualized with Axiovision software at 10x 
magnification. PTX3 protein expression in carotid arteries was analyzed as described 
[41, 85]. 
Platelet aggregation 
Citrated blood was diluted with HEPES-Tyrode buffer (137 mM NaCl, 20 mM 
HEPES, 5.6 mM glucose, 0.35% bovine serum (BSA), 1 mM MgCl2, 2.7 mM KCl, 
3.3 mM NaH2PO4) and centrifuged. Washed platelets, obtained by serial 
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centrifugations of PRP with the addition of PGI2 and apyrase, were adjusted to 250 x 
10
3
 platelets/ μL, and aggregated by Born turbidimetric technique in presence of 
collagen (0.5 or 1µg/mL), ADP (0.5 or 1µM) and fibrinogen (0.25 mg/mL). For 
some experiments PTX3, its C-terminal or N-terminal domain (1µg/mL) were 
incubated for 1 hour at RT with fibrinogen (IMMUNO AG, Italy – ratio 1:10) or 
overnight at 4°C with collagen (Mascia Brunelli, Italy – ratio 1:1). As controls, same 
conditions were used for samples without PTX3 and its domains. Samples were 
incubated in an acid solution [70] (Diluent B, Mascia Brunelli, Italy). To exclude 
unspecific binding to collagen, the ability of collagen preincubated with BSA 
(1µg/mL, same experimental conditions used for PTX3) to stimulate aggregation was 
tested and resulted similar to that of collagen without preincubation with BSA (data 
not shown). 
Diet induced obesity model 
PTX3 KO and WT mice at 12 weeks of age were switched from the standard diet 
(Chow diet,  12% of the calories from fat) to an high fat diet (HFD), as a model of 
diet-induced obesity. Some WT mice were fed to a standard fat diet (SFD) and 
compared to WT mice fed to HFD. Both HFD and SFD were given for 20 weeks. 
HFD composition 
 Protein    24 g%             20 kcal% 
 Carbohydrate   41 g%             35 kcal% 
 Fat    24 g%             45 kcal% 
 Total        4,13 kcal/g 100 kcal% 
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SFD composition 
 Protein    19,2 g% 20 kcal% 
 Carbohydrate    67,3 g% 70 kcal% 
 Fat     4,3  g% 10 kcal% 
 Total         3,85 kcal/g 100 kcal% 
The diet was administered 3 times a week and food intake was measured daily for 4 
weeks during both the HFD and SFD treatment. Body weight was measured weekly.   
Glucose (GTT) and insulin (ITT) tolerance test 
The impairment of glucose metabolism was investigated with the GTT and ITT tests. 
For the GTT, mice were left fasting overnight and the day after basal glycaemia was 
measured, with a commercial kit for glycaemia measurement, from a drop of blood 
taken from mouse tail. Soon after, a solution of glucose (20% w/v in PBS) was 
injected in the peritoneum and the glycaemia checked after 15, 30, 60, 90 and 120 
minutes from injection. For the ITT, mice were left fasting for 4 hours; then basal 
glycaemia was measured and a solution of insulin (0,1mU/µL) was injected in the 
peritoneum. As described for GTT, glycaemia was checked after 15, 30, 60, 90 and 
120 minutes from injection.  
Magnetic resonance for imaging (MRI) 
MRI is a test that uses a magnetic field and pulses of radio wave energy to make 
pictures of organs and structures inside the body. The MRI was used to monitor fat 
accumulation in the visceral, subcutaneous and intrascapular depots after 10 and 20 
weeks of HFD in WT and PTX3 KO mice. Mice were anesthetize with isoflurane 
during the MRI analysis. The identification of fat was allowed by the different 
amount of water of this tissue compared to muscles: fat depot appeared white while 
muscles black. A total of 16 pictures were taken from the visceral and scapular area; 
then the area of fat depot was measured in 3 pictures per mouse and the average 
calculated.  
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Real time quantitative polymerase chain reaction 
0,5 – 1 ng of RNA was reverse transcripted from the thoracic aorta or 30 mg of 
adipose tissue. Two μL of cDNA were amplified by realtime quantitative PCR with 
1X Syber green universal PCR mastermix (BioRad, Italy). The specificity of the 
Syber green fluorescence was tested as described [286]. Each sample was analyzed 
in duplicate using the CFX-Cycler (BioRad). The PCR amplification was related to a 
standard curve ranging from 10-11 mol/L to 10-14 mol/Land data were normalized 
for the housekeeping gene ribosomal protein L13a (RLP13a) [71]. 
Adipose tissue digestion and analysis of leukocyte infiltration 
Epididymal and subcutaneous fat were isolated and cut into small pieces in a solution 
of collagenase I in BSA 5% and 5mM CaCl2 and incubated for 40 minutes at 37°C. 
To isolate the stromovascular fraction, digested solution of fat was centrifuged, 
washed in PBS and filtered with a 70 µM cell strainers. Cells were count and stained 
with 1 µL of Fc block, to prevent unspecific binding for 30 minutes at 4°C. Later 
cells were washed and stained with 2 µL of CD45 PerCP Cy 5.5, 1 µL of CD11b 
BV421, 1 µL of Ly6G PE, 1 µL of Ly6C FITC, 1,5 µL of F4/80 PECy7. Cells were 
analyzed with the BD Aria Sorter.  
Statistical analysis 
Statistical analyses were performed with GraphPad Prism6 or with IBM-SPSS 
statistic. Data were analyzed by the Wilcoxon rank-sum test or by ANOVA with 
repeated measures for main effects of treatment time and genotype, followed by a 
Bonferroni post hoc analysis. Data are presented as mean ± SEM. 
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PTX3 plays a protective role in arterial thrombosis 
To unravel the role of PTX3 in the context of arterial thrombosis in experimental 
models, FeCl3 induced carotid artery thrombosis (Figure 7A) was evaluated in PTX3 
KO and WT animals. Of note, under basal conditions PTX3 KO and WT present a 
similar blood flow in the carotid artery (0.67±0.03 mL/min vs 0.60±0.04 mL/min 
respectively, mean ± SEM are reported); instead, application of FeCl3 10% resulted 
in a reduction of blood flow after 30 minutes of -65.2±8.8% for PTX3 KO and -
20.2±7.2% for WT (mean ± SEM are reported, p<0.01; Figure 8A). Furthermore, 
analysis of the area under the curve of carotid blood flow supported the latter results 
as PTX3 KO mice presented a significantly decreased AUC compared to WT 
(p<0.01; Figure 8B) and these findings were also corroborated by histological 
analysis of injured carotid arteries which showed increased thrombi occlusion in 
PTX3 KO than WT vessels (Figure 8C, 8D). These data demonstrated that PTX3 
plays a protective role during arterial thrombosis. 
PTX3 deficiency in vascular cells but not in myeloid cells is associated with 
increased arterial thrombosis 
To disentangle the contribution of bone marrow (BM) cells and of vascular cells in 
the increased arterial thrombosis observed in PTX3 KO mice, we performed the 
FeCl3 arterial thrombosis experiment in irradiated PTX3 KO mice reconstituted with 
the BM of PTX3 KO or WT mice (PTX3 KO/BMT_PTX3 KO or PTX3 
KO/BMT_WT) and in irradiated WT reconstituted with the BM of PTX3 KO or WT 
mice (WT/BMT_PTX3 KO or WT/BMT_WT) (Figure 9A). Following the 
application of FeCl3 (10%), WT transplanted with BM of PTX3 KO behaved 
similarly in terms of arterial thrombosis to WT transplanted with BM of WT 
(reduction of blood flow after 30 minutes of -45.5±1.4% for WT/BM_WT and -
53.4±9.8% for WT/BM_PTX3 KO; Figure 10A) with a similar AUC of blood flow 
during the 30 minutes after FeCl3 application (Figure 10B). In contrast, PTX3 KO 
transplanted with BM of WT or with BM of PTX3 KO showed a similar reduction of 
carotid artery blood flow (reduction of blood flow after 30 minutes of -80.4±11.5% 
for PTX3 KO/BM_WT and -95.5±4.5% for PTX3 KO/BM_PTX3 KO; Figure 10A) 
and in the AUC of blood flow (Figure 10B) compared to WT mice transplanted with 
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both BM of PTX3 KO and WT (p<0.05). The differences between groups in carotid 
arterial thrombus formation were further confirmed by histological analysis (Figures 
from 10C to 10F). These data suggest a critical role of PTX3 originated from the 
vessel wall in the modulation of thrombus formation observed in PTX3 KO mice 
while limit the role of PTX3 stored and acutely released by neutrophils described in 
cardiovascular events [108]. 
In agreement with this, PTX3 plasma levels, after arterial thrombosis, were similar in 
WT mice transplanted with either WT or PTX3 KO bone marrow, while the protein 
was not detectable in PTX3 KO mice independently of being transplanted with WT 
or PTX3 KO bone marrow (Figure 10G).  
PTX3 protective activity does not dependent on P-selectin modulation  
We next addressed whether PTX3 protective role derived from the modulation of P-
selectin; indeed, P-selectin is a key player of platelet-platelet, platelet-leukocyte and 
platelet-endothelium interaction during thrombosis [287] and it is targeted by PTX3 
to dampen neutrophils recruitment [57]. Thus, increased P-selectin-dependent 
thrombotic response might represent a logical mechanism to explain the pro-
thrombotic phenotype observed in PTX3 KO mice [70]. To address this issue, we 
generated P-selectin/PTX3 double KO mice (P-selectin/PTX3 DKO) and 
investigated carotid blood flow following arterial thrombosis in these animals 
compared to P-selectin KO mice.  
Following the application of FeCl3 (10%), P-selectin/PTX3 DKO showed increased 
arterial thrombosis compared to P-selectin KO mice, with a reduction of blood flow 
after 30 minutes of -32.4±7% for P-selectin KO and -90.5±11% for P-selectin/PTX3 
DKO (mean ± SEM are reported, p<0.01; Figure 11A). The AUC of blood flow 
during the 30 minutes after FeCl3 application was significantly higher for P-selectin 
KO compared to P-selectin/PTX3 DKO (p<0.01; Figure 11B), indicating a 
significant increased arterial thrombosis in DKO mice as confirmed by histological 
analysis (Figures 11C-11D). Of note, the lack of both proteins resulted in a 
thrombotic phenotype similar to that observed in PTX3 KO mice, while the only 
absence of P-selectin was not able to induce the formation of a thrombus, thus 
suggesting that the protection toward arterial thrombosis exerted by PTX3 might be 
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independent on P-selectin modulation. Given the partial resistance of P-selectin KO 
to FeCl3 induced arterial thrombosis, we next investigated the effect of a more robust 
induction of arterial thrombosis in these mice (application of FeCl3 20%), to study 
whether PTX3 deficiency could affect thrombus formation and leukocyte recruitment 
in the context of P-selectin deficiency. In spite of larger thrombi observed in P-
selectin/PTX3 DKO compared to P-selectin KO (Figures from 12A to 12C; 
p<0.05), leukocytes recruitment in the thrombus (Figure 12D) and the percentage of 
circulating platelet-leukocyte aggregates, after 30 minutes from FeCl3 application 
(Figure 12E), were not significantly different between P-selectin KO and P-
selectin/PTX3 DKO. The latter findings suggested also that the increased thrombus 
formation in DKO was not dependent on a different leukocyte recruitment during 
thrombosis. In line with this, ADP stimulation of whole blood from PTX3 KO and 
WT mice resulted in a similar percentage of platelet-leukocyte aggregates (Figure 
12F). These observations limit the relevance of the interaction between PTX3 and P-
selectin during arterial thrombosis and suggest that PTX3 produced by myeloid cells, 
including the protein stored in neutrophils, does not contribute to the protection 
toward arterial thrombosis. 
PTX3 deficiency does not affect platelet activation and hemostatic properties  
In line with the previous results showing a marginal role of PTX3 in hematopoietic 
cells, we confirmed that PTX3 deficiency had no effect on platelets aggregation 
(Figures 13A-13B) and function in terms of P-selectin expression and integrin 
αIIbβIII activation after stimulation with various agonists (Figures 13C-13F). This 
finding was corroborated, in vivo, by the observation of a similar mice survival 
following pulmonary thromboembolism induced by rapid intravenous administration 
of a mixture of collagen and epinephrine (50% for PTX3 KO and 55.5% for WT 
mice respectively, Figure 14A-14B), thus limiting a direct effect of PTX3 deficiency 
on platelet function. 
Furthermore, PTX3 KO and WT mice had similar number of circulating platelets 
(Figure 15A), comparable plasma fibrinogen levels (Figure 15B) and tail bleeding 
time (Figure 15C). In addition, similar prothrombin time (PT) and activated partial 
prothrombin time (APTT) were measured in the two groups of mice under basal 
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conditions (Figure 15D-15E). Finally, we excluded that the increased thrombosis 
observed in PTX3 KO mice was a consequence of an impaired expression of tissue 
factor (TF) by the vessel wall as aortas from PTX3 KO and WT presented a similar 
TF expression of mRNA level (Figure 15F). 
PTX3 acts at the interface between the damaged vascular wall and the thrombus by 
dampening fibrinogen and collagen pro-thrombotic effects 
Following arterial thrombosis, PTX3 localized mainly at the interface between the 
damaged endothelium and the thrombus (Figure 16A), and co-localized with fibrin 
(Figure 16B). Furthermore, based on the recent observation that PTX3 deficiency 
induces fibrin deposition after tissue injury [70], we investigated whether the 
interaction of PTX3 with fibrinogen [70] and/or with extracellular matrix 
components could explain the phenotype observed.   
Therefore, we initially performed platelet aggregation with fibrinogen with or 
without the pre-incubation with PTX3 or its domains. Although platelet aggregation 
was significantly reduced by 18.72% ± 5.20% when fibrinogen was pre-incubated 
with PTX3 (mean ± SE are reported, p<0.01; Figure 16C), an effect dependent on 
the PTX3 N-terminal domain (- 32.50% ± 6.61%, mean ± SE are reported, p<0.01; 
Figure 16C), this reduction was not enough to explain the phenotype observed in 
vivo. We thus tested the ability of collagen pre-incubated with PTX3 to induce 
platelet aggregation. Of note, under this condition, a decreased platelet aggregation 
by 38.67% ± 3.17% compared to collagen alone was observed (mean ± SE are 
reported, p<0.01; Figure 16D). Interestingly, PTX3 tuning of collagen induced 
platelet aggregation was dependent on the C-terminal domain (-44.17% ± 5.53%, 
mean ± SE are reported, p<0.01; Figure 16D). Finally, we reported that the pre-
incubation of either fibrinogen and collagen with PTX3 resulted in a synergic effect 
with a reduction by -35.83% ± 2.19% of platelet aggregation when fibrinogen and 
collagen were pre-incubated with PTX3 compared to fibrinogen and collagen alone 
(mean ± SE are reported, p<0.001; Figure 16E). Furthermore, the observation that 
N-terminal domain appears to be more selective for fibrinogen while PTX3 C-
terminal domain appears to be more selective for collagen supported the hypothesis 
that PTX3 might dampen both fibrinogen and collagen effect, resulting in a 
Results 
55 
 
synergistic control of their pro-thrombotic activity. Indeed, when platelet aggregation 
was investigated in cells treated both with fibrinogen incubated with PTX3 N-
terminal domain and with collagen pre-incubated with PTX3 C-terminal domain, a 
significant reduction of -46% ± 8.81% compared to collagen and fibrinogen alone 
was observed (mean ± SE are reported, p<0.001; Figure 16E), suggesting a 
synergistic effect of PTX3 in vitro. 
Administration of recombinant human PTX3 protects from arterial thrombosis 
Data collected so far suggested the possibility that the protective effect of PTX3 on 
platelet aggregation could be the result of a synergistic control of collagen and 
fibrinogen pro-thrombotic activity. To extend these findings in vivo, we tested 
whether human recombinant PTX3 (hPTX3) was able to revert the prothombotic 
phenotype observed in PTX3 KO mice. Mice were injected i.v. with human 
recombinant PTX3 (5 mg/kg) [57, 282] followed by FeCl3 (10%) injury. While 
PTX3 KO mice injected with PBS showed a reduction in carotid artery blood flow of 
-60.8% ± 7.7%, PTX3 KO mice injected with hPTX3 presented a reduction of -
11.8% ± 7.3% (p<0.05; Figure 17A); the AUC of blood flow during the 30 minutes 
after FeCl3 application was significantly higher in PTX3 KO mice injected with 
hPTX3 compared to PTX3 KO mice injected with PBS (p<0.01; Figure 17B) and 
was further confirmed by histological analysis (Figure 17C, 17D). Similar results 
were observed when the effect of PTX3 injection was tested in wild type mice 
following FeCl3 (20%) injury. All WT mice injected with PBS showed a reduction in 
carotid artery blood flow of -88.9% ± 7.4% compared to WT mice injected with 
hPTX3 which presented a reduction of -60.9% ± 14,8% (Figure 17E) and the AUC 
of blood flow during the 30 minutes after FeCl3 application was significantly higher 
in WT mice injected with hPTX3 compared to WT mice injected with PBS (p<0.05; 
Figure 17F) as was thrombus formation (Figure 17G-17H).  
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PTX3 deficiency protects mice from diet induced obesity 
During this PhD project we were also aimed at investigating the role of PTX3 in 
other immuno-inflammatory diseases, as the case of obesity and its related metabolic 
impairment. To validate the use of high fat diet (HFD, 45% of calories from fat) as a 
model of diet-induced obesity, we first compared the effect of this diet to a control 
diet (SFD, 10% of calories from fat) in WT animals. We observed that WT mice fed 
to HFD presented a significant increment of weight gain compared to those fed to 
SFD just after 4 weeks of diet (p<0.01; Figure 18A), as also demonstrated by the 
measurement of the area under the curve of weight gain versus time (p<0.001; 
Figure 18B); however, we excluded that this result was a consequence of a different 
palatability of the HFD as both groups presented a similar daily food intake (Figure 
18C). WT mice fed to HFD also developed glucose intolerance compared to SFD 
mice as shown by a significant increased levels of plasma glucose during glucose 
tolerance test (Figure 18D), confirmed by the area under the curve of glucose plasma 
levels versus time (p<0.05; Figure 18E). We also confirmed that the prolongation of 
HFD resulted in a further increment of body weight (p<0.001; Figure 19A), 
elevation of basal glycaemia (p<0.01; Figure 19B) with a fall of insulin sensitivity 
(Figure 19C).  
As we confirmed that HFD was a good model to investigate obesity and metabolic 
syndrome in mice, we fed WT and PTX3 KO mice with this diet for 20 weeks. 
Although at the start of HFD both groups had a similar body weight (Figure 20A), 
during time PTX3 KO mice gained less weight compared to WT (Figure 20A) and 
presented a significantly reduced weight gain compared to WT (p<0.05; Figure 20B 
and 20C), an observation independent on food intake (Figure 20D). 
PTX3 deficiency does not impair glucose and insulin tolerance during 20 week-
HFD 
Given that obesity is the most important predisposing factor for glucose and insulin 
resistance we investigated whether the decreased weight gain due to PTX3 
deficiency further affected glucose and insulin tolerance. Basal glycaemia, after an 
overnight fasting, was similar between groups at both 10 week (Figure 21A) and 20 
weeks of HFD (Figure 21B), as well as glucose (Figure 21C-21D) and insulin 
Results 
57 
 
tolerance (Figure 21E-21F) assessed by a glucose (GTT) and insulin (ITT) tolerance 
test. These data excluded that PTX3 has a direct role on gluco- and insulin-
metabolism. 
PTX3 affects white but not brown adipose tissue deposition 
In addition to weight, we performed a quali-quantitative analysis of adipose tissue 
deposition in the visceral (VAT), subcutaneous (SCAT) and intrascapular (usually 
the area of brown adipose tissue, BAT, accumulation in mice) fat depots through 
magnetic resonance for imaging (MRI). PTX3 KO mice presented a significant 
decreased accumulation of fat both in the visceral and subcutaneous adipose tissue at 
10 weeks (p<0.05; Figure 22A-22C) and 20 weeks of HFD (p<0.05; Figure 22B-
22D). However, intrascapular fat deposition was similar between WT and PTX3 KO 
mice at both 10 and 20 weeks of HFD (Figure from 22E to 22G). These results 
correlate the decreased weight gain in PTX3 KO mice with a decreased deposition of 
white adipose tissue (VAT and SCAT); however we excluded a different 
thermoregulation and energy expenditure in PTX3 KO mice since brown adipose 
tissue (BAT) depots were similar to those of WT. 
PTX3 impairs the inflammatory response associated to visceral adipose tissue 
Central obesity is a key feature of metabolic syndrome and it’s the place where 
inflammation perpetuates; therefore, given that PTX3 is a key molecule of immune 
response, we have recently started investigating the immune-inflammatory response 
which takes place in white adipose tissue. Histological analysis showed that size of 
adipocytes was significantly smaller in visceral adipose tissue (VAT) of PTX3 KO 
compared to WT (p<0.01; Figure 23A-23C), while a similar size was observed in 
adipocytes from subcutaneous adipose tissue (SCAT) between WT and PTX3 KO 
mice (Figure 23B-23D). We also observed that VAT of PTX3 KO mice presented a 
decreased infiltration of immune cells (leukocytes, Figure 24A) and reduced 
expression of the pro-inflammatory cytokines MCP-1 and IL-6, while no difference 
was noticed in the expression of IL-10 (p<0.05; Figure 24B). These data suggested 
that the reduced expansion of white adipose tissue in PTX3 KO mice might be 
strictly associated to a limited immune-inflammatory response to HFD treatment. 
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Aim of this PhD project was to investigate the role of the long pentraxin 3 (PTX3) in 
two common morbidities that affect particularly Western countries: arterial 
thrombosis, a critical complication of atherosclerotic plaque rupture (correlated with 
the clinical manifestation of myocardial infarction and stroke), obesity and its related 
metabolic complications, a worldwide epidemic with increasing socioeconomic cost. 
PTX3 belongs to the pentraxin superfamily, soluble, multifunctional, pattern 
recognition proteins, and is an essential component of the humoral arm of innate 
immunity. More recently, it’s role in cardiometabolic diseases has gained attention 
and PTX3 has emerged as a key acute phase protein associated to inflammation in 
cardiovascular disorders, including heart failure, atherosclerosis, acute coronary 
syndromes and peripheral vascular diseases [138, 288, 289]. Although PTX3 is a 
prognostic marker of acute myocardial infarction, [290] genetically determined high 
PTX3 levels do not influence the risk of AMI, suggesting that PTX3 concentration 
itself is unlikely to be even a modest causal factor for AMI [149]. However, PTX3 
plasma levels were found to be both positively associated with predisposing factors 
of metabolic syndrome as BMI, insulin plasma levels, low HDL and high 
triglycerides, [119, 121] but also negatively correlated with gluco-stimulated insulin 
secretion. [122] On the other hand, data from animal models point to a protective 
function of the protein: PTX3 overexpression limits neointimal thickening after 
balloon injury of rat carotid artery [76], while PTX3 KO mice, following 
ischemia/reperfusion (I/R) injury, present a significantly larger infarcted area 
compared to WT mice [41]. PTX3 deficiency has been also associated with increased 
atherosclerosis, increased macrophage accumulation and inflammation in the 
atherosclerotic lesions [85], and, more recently, to the recruitment of anti-
inflammatory macrophages, promotion of angiogenesis and tumor growth [117]. The 
observations coming from animal studies point to a protective effect of PTX3 
potentially associated with the tuning of inflammation during cardiovascular diseases 
[288], however the increased levels observed in patients with cardiometabolic 
diseases indicate that PTX3 might be a bystander or represent an extreme attempt of 
the body to limit an excessive inflammatory response. 
In this project, we demonstrated that PTX3 has multifunctional roles as it is involved 
in several inflammatory processes, on one side protecting from arterial thrombosis 
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but on the other promoting adipose tissue deposition and the inflammatory response 
associated to obesity.  
In the first part of the project, we observed that PTX3 KO compared to wild type 
mice presented a significant increased carotid occlusion with a reduction of blood 
flow after FeCl3 topic application on the carotid artery, an experimental model of 
arterial thrombosis. We demonstrated that PTX3 protective effects depend on the 
protein produced by vascular cells and not myeloid cells as only the deficiency of 
PTX3 in the vasculature, but not in myeloid cells, was associated to a pro-thrombotic 
phenotype, similar to that of PTX3 KO mice. Next, we excluded that this effect was 
related to P-selectin, a ligand of PTX3, which mediates the recruitment of leukocytes 
to the activated endothelium, and also the interactions between platelets and 
leukocytes. Indeed P-selectin/PTX3 double KO mice showed an increased carotid 
artery occlusion following arterial thrombosis compared to P-selectin KO mice. This 
observation coupled with those indicating that the protection toward arterial 
thrombosis is dependent on vascular produced PTX3, that the modulation of P-
selectin activity depends on PTX3 produced by myeloid cells [57], that PTX3 plasma 
levels do not peak after arterial thrombosis, further limiting the contribution of PTX3 
derived from myeloid cells [108], excludes the role of PTX3 in mediating P-selectin 
dependent leukocyte recruitment and platelet-leukocyte interactions as a protective 
mechanism during arterial thrombosis. Moreover, the survival rate following 
pulmonary thromboembolism (a platelet restricted thrombosis model) was similar in 
PTX3 KO and WT mice as it was platelet aggregation and function (in terms of 
expression of activation markers), further excluding that PTX3 affects platelet 
activation, and pointing toward an effect dependent on increased vascular 
thrombogenicity. The latter hypothesis was further sustained by the absence of main 
differences in WT and PTX3 KO mice hemostatic properties, including fibrinogen 
levels, tail bleeding, PT and APTT. Furthermore, although PTX3 was initially 
described to induce TF expression in endothelial cells and monocytes in vitro [61, 
291], later studies failed to confirm this in vivo [70] and indeed we showed that TF 
expression in the aorta of PTX3 KO and WT mice was similar, arguing against a pro-
thrombotic effect of PTX3.  
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PTX3 localizes at the interface between damaged endothelium and thrombus rather 
than within it, in agreement with the vascular origin of the protein involved in 
arteries homeostasis. Indeed PTX3, beyond to be produced and stored by myeloid 
cells [30, 57, 292], is synthesized by several type of stromal cells including 
fibroblasts [33], smooth muscle cells [33, 35], endothelial cells [42, 293] and is a 
component of tissue extracellular matrix (ECM) [63]. PTX3 interacts with other 
components of the ECM, including the viscoelastic HA-rich matrix of the cumulus 
oophorus complex that surrounds the preovulatory follicle [62, 63], and also plays a 
critical role during tissue repair following wound healing, a mechanism which is 
dependent on the acidic microenvironment which is generated following tissue injury 
[70]. These tissue-related functions of PTX3 appear to be independent of those 
associated with acute phase conditions, such as endotoxic shock, sepsis and other 
inflammatory and infectious states, but also from myocardial infarction [60], where 
PTX3 increases in few hours and is contributed by neutrophils following the 
interaction with activated platelets [108], limits neutrophils infiltration and ROS 
generation in the ischemic area [98], thus further supporting the hypothesis for a 
different role of PTX3 produced by myeloid compared to that derived from stromal 
cells.  
Here we extend the activities played by vascular derived PTX3 which protect toward 
arterial thrombosis showing that this effect was dependent on the ability to interact 
with fibrinogen and collagen thus dampening their pro-thrombotic effects. Indeed, 
after application of FeCl3, vascular wall loose its integrity leading to the exposure of 
inner layers and particularly components of extracellular matrix, as collagen which 
triggers platelet activation and aggregation, leading to the generation of fibrin clot 
[294]. Furthermore, as PTX3 is a component of ECM (probably derived from 
endothelial, smooth muscle cells and fibroblasts) [63], and similarly it is exposed 
during arterial thrombosis (and indeed it is found on the damaged endothelium), it 
may interact with collagen and fibrinogen limiting their pro-thrombotic effects. We 
indeed demonstrated that specific protein domains of PTX3 mimicked the activity of 
the full protein with the PTX3 N-terminal domain inhibiting fibrinogen-mediated 
platelet activation and the PTX3 C-terminal domain blocking collagen effects. More 
importantly, the two domains worked synergistically to dampen both fibrinogen and 
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collagen-induced platelet aggregation. We might speculate that these interactions 
might result from the profound homology between these pro-thrombotic molecules 
and highly conserved sequences of proteins belonging to the innate immune system: 
indeed, the first component of complement C1q and other related proteins as 
collectins and ficolins which are ligands of PTX3, resulting in the activation of 
complement system, possess respectively a collagen-like region and a fibrinogen like 
domain [11, 295, 296]. Furthermore, it has been shown that the different functions 
ascribed to PTX3 might originate from the high glycosilation variability among 
PTX3 isolated from different cellular sources: this suggests that the glycosylation 
pattern might change depending on cell type and inducing stimuli, thus modulating 
the crosstalk between PTX3 with different ligands in different conditions (as 
complement components and P-selectin) [297].   
Although it is tempting to speculate that the interaction of PTX3 through its N- and 
C-terminal domain with fibrinogen and collagen respectively may dampen the 
generation of the pro-thrombotic fibrin from fibrinogen and the exposure of collagen 
during vascular injury, an effect favored by local acidification occurring during 
tissue injury [70], we cannot exclude the possibility that PTX3 might also influence 
additional pathways in the atherothrombotic response, as the fibrinolytic system; 
indeed, PTX3 through its N-terminal domain was observed to bind plasminogen and 
in vitro, fibrin gel degradation mediated by plasmin and triggered by uPA and tPA 
was potentiated in the presence of PTX3 [70].  
Finally, the observation that the injection of recombinant PTX3 rescues the 
phenotype observed in PTX3 deficient mice and improves the outcome in wild type 
mice, supports the need of further studies aimed at addressing the pharmacological 
potential of PTX3 in the context of atherothrombosis.  
More recently we have started investigating the role of PTX3 in metabolic 
complications associated to obesity; indeed, the modulation of immuno-
inflammatory response during metabolic complications is gaining growing interest, 
leading scientists to coin the new word “metainflammation” to define the 
metabolically triggered inflammation [2]. 
Both metabolic syndrome and obesity are linked to an increased incidence of 
cardiovascular diseases [215, 298], particularly due to the chronic low grade 
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inflammation which characterizes these pathological conditions [299, 300] and great 
efforts have been done to identify novel targets to control the over activation of the 
inflammatory response as pharmacological treatments [301, 302]; however, further 
studies are needed to better understand the molecular mechanisms of this 
pathological immuno-inflammatory response.  
Aim of the second part of this PhD project was to investigate how PTX3 affects the 
immuno-inflammatory response associated to obesity and adipose tissue, given that 
chronic inflammation particularly affects visceral adipose tissue [223, 303, 304], and 
PTX3 is a key molecule mediating innate immune and inflammatory responses. We 
first validated the use of high fat diet (HFD, consisting of 45% of calories from fat, a 
commonly used model of diet induced obesity) [277, 305] as a good model to study 
obesity and metabolic syndrome and following WT and PTX3 KO mice were fed 
with HFD for 20 weeks; indeed, after 16–20 weeks of HFD, mice will typically 
exhibit 20–30% increase in body weight when compared to chow-fed mice [279] and 
the full manifested picture of obesity develops with adipocyte hyperplasia, fat 
deposition in mesentery, increased fat mass, diabetes, and hypertension [281].  
We reported that, although both groups had a similar body weight at the start of 
HDF, during time PTX3 KO mice gained significantly less weight compared to WT, 
an effect independent of food intake. We failed to observed difference in glucose and 
insulin tolerance, key features of metabolic impairment associated to obesity, 
suggesting that PTX3 deficiency has not a direct effect on gluco-metabolism. In 
agreement with the decreased body weight, PTX3 KO mice presented a significant 
reduced deposition of both visceral and subcutaneous white adipose tissue, while no 
difference was observed in the deposition of the brown adipose tissue, an essential 
regulator of energetic balance. Indeed, histological characterization of white adipose 
tissue showed that the size of adipocytes was significantly smaller in the visceral, but 
not in the subcutaneous adipose tissue of PTX3 KO mice compared to wild type. 
Adipocyte hypertrophy is deeply connected with adipose tissue inflammation caused 
by the production of pro-inflammatory cytokines (MCP-1, IL-6, INFγ) and the 
recruitment of pro-inflammatory immune cells, particularly macrophages, which are 
usually polarized toward an M1, pro-inflammatory phenotype compared to 
macrophages found in the lean adipose tissue which are of the M2, anti-inflammatory 
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phenotype [237, 306, 307]. As PTX3 has been shown to be present in adipose tissue 
and its gene expression increased during obesity [34, 119, 122], we hypothesized a 
role in modulating visceral adipose tissue inflammation thus leading to an impaired 
expansion of adipose tissue. Indeed, both in humans and mice visceral adipose tissue, 
PTX3 gene expression has been found to be directly related to TNFα expression in 
the same tissue [34, 119]. Furthermore, in humans, body mass index (BMI) is 
significantly correlated with circulating levels of pro-inflammatory cytokines, and 
among those, TNFα; therefore we might speculate that the increased plasma levels of 
PTX3, observed in association with cardiometabolic risk factors, are the mirror of 
those of TNFα. However, our data suggest that PTX3 during HFD is not just a 
bystander of the immune-inflammatory response associated to obesity, but plays an 
active role: indeed, we observed that the deficiency of PTX3 correlates with a 
decreased recruitment of leukocytes in the visceral adipose tissue, which is an event 
directly associated with the degree of inflammation and expansion of the tissue [303, 
308]; furthermore, the evidence of a decreased inflammation of visceral adipose 
tissue of PTX3 KO mice came from the analysis of gene expression of pro-
inflammatory cytokines (MCP-1 and IL-6) which was significantly decreased 
compared to WT. This observation seems to be in line to what reported in tumor 
context: PTX3 deficiency has been associated to cancerogenesis thanks to its ability 
to promote an M2 versus M1 macrophage polarization, which is detrimental for 
tumor growth [117]. Therefore, we might speculate that PTX3 deficiency, promoting 
the switch toward the M2 versus M1 subsets of macrophages, decreased the immuno-
inflammatory response of visceral adipose tissue leading to a reduced accumulation 
of white adipose tissue and thus protecting PTX3 KO mice toward diet induced 
obesity. However, much work needs to be done to better characterize the mechanism 
behind the reduced expansion of visceral adipose tissue in PTX3 KO mice: identify 
the phenotype of immune cells infiltrating white adipose tissue, the source of PTX3 
which in the context of visceral obesity plays a detrimental role, and how a decreased 
immuno-inflammatory response leads to reduced fat deposition. Furthermore we still 
have to provide a better metabolic phenotype of mice fed to HFD with the 
measurement of plasma triglycerides, cholesterol, insulin levels, to check the 
deposition of ectopic fat (as the case of the liver) and explain why, even though 
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visceral adiposity, the most important predisposing factor for insulin resistance, 
[309] is decreased in PTX3 KO mice, glucose and insulin sensitivity are similar to 
those of WT mice. As a key molecule of immune system, PTX3 might not directly 
affect metabolic profile during the early stages of HFD feeding, but modulate the 
immuno-inflammatory response which follows visceral adipose tissue deposition, 
probably favoring metabolic dysfunction. Therefore, a prolongation of the diet is 
likely to exacerbate a difference in the metabolic phenotype of PTX3 KO mice, thus 
leading to reveal an intimate connection between immuno-inflammatory response 
and metabolic dysfunctions. 
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Conclusions  
Concluding, my PhD project has shown the multifunctional role of the long pentraxin 
3 which plays a protective role in arterial thrombosis, while in a model of diet-
induced obesity is associated with the promotion of inflammation and fat deposition 
in the visceral adipose tissue. These contrasting results are not surprising as PTX3 
has been shown to be produced by a variety of cell types under pro- and anti-
inflammatory stimulation and play multifunctional roles; furthermore, depending on 
the insult that triggers the inflammatory response, PTX3 effects might be affected: 
while FeCl3-induced arterial thrombosis represents an acute inflammatory response, 
the HFD feeding exacerbates a chronic inflammation in which visceral adiposity 
significantly correlates with circulating levels of pro-inflammatory cytokines, as IL-6 
and TNFα; we might speculate that, as PTX3 gene expression directly correlates with 
TNFα, it is likely that PTX3 overexpression worsen the resolution of inflammation 
during obesity. Finally, the highly variable glycosylation pattern, depending on the 
cell source, suggests that PTX3 may play different functions depending on the origin 
and the site of action. Therefore, it is tempting to propose further studies aimed at 
addressing a possible cell and/or tissue promotion or inhibition of PTX3 as a new 
pharmacological target for the treatment of cardiometabolic diseases.       
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Figure 1. Signaling pathways involved in classical inflammation and 
metaflammation  
Left, classical inflammation: pathogens acutely and robustly activate inflammatory 
kinases in immune cells causing a catabolic, 'hot' state of increased energy 
expenditure, and proinflammatory pathways are activated. This results in the 
recruitment of more immune cells via cytokines, causing acute insulin resistance 
(and enhanced glucose use through non–insulin-mediated pathways). Middle, 
metaflammation: metabolically induced, chronic, low-grade and 'cold' inflammation 
occurring in metabolic tissues that involves stromal and resident immune cells 
without an increase in basal energy expenditure. There is some overlap in the 
repertoire of inflammatory kinases and downstream events in both scenarios, except 
that insulin resistance persists in an anabolic state in metaflammation. Reilly et al. 
[310] now show that this paradox can be managed by a pharmacological intervention 
to suppress chronic inflammation, restore insulin sensitivity and increase energy 
expenditure by targeting IKKε and TBK1. IRFs, interferon-regulated factors [311].
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Figure 2. Overview of pentraxins in innate immunity  
Pentraxins constitute a superfamily of multifunctional multimeric proteins that are 
phylogenetically conserved from arachnids to mammals. They are divided in short 
pentraxin (CRP and SAP), which are mainly produced by the liver in response to IL-
6, and long pentraxins (PTX3), which are produced by a variety of cells after both 
pro- and anti-inflammatory stimulation. Together, they contribute to the humoral arm 
of innate immunity, promoting the opsonization, regulating complement activation 
and discriminating self from non-self components. (IL interleukin, TLR toll-like 
receptor, TNF tumour necrosis factor, CRP C-reactive protein, SAP serum amyloid 
P-component, PTX pentraxin) [312].  
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Figure 3. Effects of PTX3 in cardiovascular diseases  
Increased PTX3 plasma levels are observed during myocardial infarction (MI) and 
atherosclerosis and the deficiency results in a marked heart damage after MI and a 
more inflamed atherosclerotic plaque. Functional PTX3 interacts with a) FGF2 and 
inhibits its activity, thus dampening SMCs proliferation and migration associated to 
restenosis, and b) P-selectin thus reducing the recruitment of leukocytes associated to 
tissue damage and inflammation [288].    
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Figure 4. Occlusive arterial thrombi at sites of atherosclerosis plaque rupture.  
A platelet-rich thrombus (white thrombus or platelet-rich mural thrombus) builds up 
on the surface of a disrupted atherosclerotic plaque, beginning in the intima and 
propagating into the intraluminal space, where it can induce major hemodynamic 
changes at the site of injury. A red thrombus, composed of red blood cells and fibrin, 
preferentially forms in the low flow recirculation zones on the downstream margin of 
the developing thrombus (adapted from [313]).  
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Figure 5. Pathophysiology of the metabolic syndrome (insulin resistance) 
Superimposed and contributory to the insulin resistance produced by excessive FFA 
is the paracrine and endocrine effect of the pro-inflammatory state. Produced by a 
variety of cells in adipose tissue including adipocytes and monocyte-derived 
macrophages, the enhanced secretion of interleukin-6 (IL-6) and tumor necrosis 
factor alpha (TNF-α) among others results in more insulin resistance and lipolysis of 
adipose tissue triglyceride stores to circulating FFA. IL-6 and other cytokines also 
are increased in the circulation and may enhance hepatic glucose production, the 
production of VLDL by the liver and insulin resistance in muscle. Cytokines and 
FFA also increase the production of fibrinogen and plasminogen activator inhibitor-1 
(PAI-1) by the liver that complements the overproduction of PAI-1 by adipose tissue. 
This results in a pro-thrombotic state. Reductions in the production of the anti-
inflammatory and insulin sensitizing cytokine adiponectin are also associated with 
the metabolic syndrome and may contribute to the pathophysiology of the syndrome. 
PAI1=plasminogen activator inhibitor 1; FFA=free fatty acids; (adapted from [314]).  
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Figure 6. Obesity-associated adipose tissue inflammation 
In the lean state, immune cells in adipose tissues (primarily resident M2-like 
macrophages together with T regulatory (Treg) cells and eosinophils) synthesize IL-
10, IL-4, and IL-13 and help to maintain an anti-inflammatory environment that 
contributes to the insulin-sensitive state. Obesity drives a shift in the number and 
phenotype of immune cells. Monocytes are recruited from the blood into the obese 
adipose tissue, where they become M1 polarized and produce pro-inflammatory 
cytokines, including TNF-α, IL-1β, and IL-6, which contribute to insulin resistance. 
Other changes contributing to the pro-inflammatory state include decreased numbers 
of eosinophils and Tregs, and increased numbers of neutrophils, B cells, mast cells, 
and interferon γ–producing Th1 and CD8+ T cells. The pro-inflammatory cytokines 
and chemokines act in autocrine, paracrine, and endocrine manners to promote 
inflammation and insulin resistance in adipose and other target tissues [315].  
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Figure 7. Experimental model of arterial thrombosis induced by FeCl3 10% 
 Panel A: representative pictures of FeCl3 injury assay; a FeCl3 saturated filter paper 
is applied on the exposed carotid artery for 3 minutes followed by blood flow 
measurement with an ultra-sonographic probe.   
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Figure 8. PTX3 KO mice show an enhanced thrombus formation in vivo after topic 
application of FeCl3 10% 
Panel A: carotid artery blood flow in PTX3 KO and WT mice after topic application 
of FeCl3 (10%); data, expressed as relative percentage to the value before injury, are 
mean ± SEM, PTX3 KO n=17, WT n=11, * p<0.01. Panel B: area under the curve 
(AUC) of carotid artery blood flow during 30 minutes of observation after topic 
application of FeCl3 10% to PTX3 KO and WT; data shown are mean ± SEM, * 
p<0.01. Panel C, D: representative hematoxylin and eosine (H/E) stained cross-
sections of carotid arterial thrombi from PTX3 KO and WT mice, scale bar=100μm. 
Panel E: PTX3 plasma levels after 30 minutes FeCl3 20% treatment; data were 
obtained from plasma of WT mice with ELISA sandwich test and are mean ± SE, 
basic levels n=4, after FeCl3 n=3. 
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Figure 9. Bone marrow transplantation in WT and PTX3 KO mice 
Panel A: Generation of WT and PTX3 KO bone marrow transplanted mice by 
myeloablative irradiation of WT and PTX3 KO recipient followed by transplantation 
of bone marrow isolated from WT and PTX3 KO mice.   
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Figure 10. PTX3 KO mice bone marrow transplanted with BM from WT and PTX3 
KO show an enhanced thrombus formation in vivo compared to WT mice 
transplanted with BM from WT and PTX3 KO mice after topic application of 
FeCl3 10% 
Panel A: carotid artery blood flow in BM transplanted (BMT) PTX3 KO and WT 
mice expressed as relative percentage to the value before injury; data shown are 
mean ± SEM, * p<0.01 WT/BMT_WT (n=4) vs PTX3 KO/BMT_WT (n=6) and 
PTX3 KO/BMT_KO (n=4), ° p<0.05 WT/BMT_PTX3 KO (n=6) vs PTX3 
KO/BMT_KO (n=6). Panel B: area under the curve (AUC) of carotid artery blood 
flow during 30 minutes of observation after topic application of FeCl3 10%; data 
shown are mean ± SEM, * p<0.05 WT/BMT_WT vs PTX3 KO/BMT_WT and 
PTX3 KO/BMT_KO; ° p<0.05 WT/BMT_PTX3 KO vs PTX3 KO/BMT_WT and 
PTX3 KO/BMT_KO. Panel C-F: representative hematoxylin and eosine (H/E) 
stained cross-sections of carotid arterial thrombi from BMT mice, scale bar=100μm. 
Panel G: PTX3 plasma levels after 30 minutes FeCl3 treatment (10%); data were 
obtained from plasma with ELISA sandwich test and are mean ± SEM.  
  
Figures  
79 
 
 
 
Figure 11. Protective effect of PTX3 goes beyond the interaction with P-selectin (I) 
Panel A: carotid artery blood flow in P-selectin KO and P-selectin KO/PTX3 KO 
mice after topic application of FeCl3 (10%); data, expressed as relative percentage to 
the value before injury, are mean ± SE, n=5/group, * p<0.01. Panel B: area under the 
curve (AUC) of carotid artery blood flow during 30 minutes of observation after 
topic application of FeCl3 10%; data shown are mean ± SEM, ** p<0.01. Panel C-D: 
representative hematoxylin and eosine (H/E) stained cross-sections of carotid arterial 
thrombi from P-selectin KO and P-selectin KO/PTX3 KO mice after FeCl3 10% 
treatment, scale bar=100μm.  
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Figure 12. Protective effect of PTX3 goes beyond the interaction with P-selectin 
(II) 
Panel A-B: representative hematoxylin and eosine (H/E) stained cross-sections of 
carotid arterial thrombi from P-selectin KO and P-selectin KO/PTX3 KO mice after 
FeCl3 20% treatment, scale bar=100μm. Panel C: measure of area thrombi after 
arterial thrombosis (FeCl3 20%) performed in P-selectin KO and PTX3 KO/P-
selectin KO mice; data are mean ± SEM; n=4/group, * p<0.05. Panel D: number of 
leukocytes within thrombi from P-selectin KO and P-selectin KO/PTX3 KO after 
FeCl3 20% treatment; data shown are mean of leukocyte count from 4 sections taken 
along the length of carotid artery ± SEM, n=4/group. Panel E: percentage of platelet-
leukocyte aggregates in whole blood from P-selectin KO and P-selectin KO/PTX3 
KO after FeCl3 20% treatment; data shown are mean ± SEM, n=4/group. Panel F: 
Percentage of platelet-leukocyte aggregates after whole blood stimulation with 
adenosine diphosphate (ADP) for 30 second and 1 minute; samples were treated with 
fluorescence-conjugated anti-mouse monoclonal antibodies CD42c FITC and CD45 
PE and analyzed using a flow cytometer; data shown are mean ± SEM, n=7/group. 
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Figure 13. PTX3 deficiency does not impair platelet activation (I) 
Panel A-B: aggregation of platelet from WT and PTX3 KO mice induced by 
collagen (0.5 and 1 ug/mL) and ADP (0.5 and 1 uM). Panel C-E: expression of P-
selectin and activation of integrin αIIbβIII from PTX3 KO and WT PRP incubated 
with the analogous of thromboxane, U46619 (10 μM), or collagen (10 μg/mL); 
samples were treated with fluorescence-conjugated anti-mouse monoclonal 
antibodies CD42c FITC and CD62P PE, or CD42c FITC and integrin α2β3 PE (active 
form). The expression of each surface antigen was analyzed using a flow cytometer. 
Panel D-F: representative pictures from cytofluorimetric analysis of P-selectin and 
integrin αIIbβIII fluorescence intensity on platelet surface in basal condition or after 
stimulation with U46619 and collagen.   
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Figure 14. PTX3 deficiency does not impair platelet activation (II)  
Panel A: survival curve after intravenous injection of collagen (11.5 μg) and 
epinephrine (1.4 μg) in PTX3 KO and WT mice (weight: 22-26 g); WT n=9, PTX3 
KO n=12. Panel B: representative hematoxylin and eosine (H/E) stained cross-
sections of lungs from mice. Arrows indicate thrombi. Scale bars= 100. 
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Figure 15. PTX3 deficiency does not impair platelet homeostasis and hemostatic 
properties 
Panel A: platelet count in WT and PTX3 KO mice; data shown are mean ± SEM, 
n=13/group. Panel B: fibrinogen plasma levels detected with ELISA test, data are 
expressed as units NIH/mL and are a mean ± SEM, WT n=7, PTX3 KO n=6. Panel 
C: tail bleeding time, data are expressed as seconds of tail bleeding and are mean ± 
SEM, WT n=6, PTX3 KO n=4. Panel D: prothrombin time (PT) and Panel E: 
activated partial thromboplastin time (APTT) of WT and PTX3 KO mice; data 
shown are mean ± SEM, n=5/group. Panel F: mRNA expression of TF from PTX3 
KO and WT aortas; data shown are mean ± SD, n=6/group. 
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Figure 16. Protective effect of PTX3 is mediated through its interaction with 
collagen and fibrinogen 
Panel A-B: immunohistochemistry analysis of PTX3 from thrombi from WT carotid 
artery after topic application of FeCl3 (10%) scale bar=100μm. Panel C: platelet 
aggregation following stimulation with fibrinogen (0.25 mg/mL), fibrinogen pre-
incubated with PTX3 (1μg/mL, 1 h RT), fibrinogen pre-incubated with PTX3 C-
terminal domain (1μg/mL, 1 h RT) and  fibrinogen pre-incubated with PTX3 N-
terminal domain (1μg/mL, 1 h RT). Data shown are mean ± SEM; * p<0.001, n=3 
and 4/group. Panel D: platelet aggregation following stimulation with collagen (1 
μg/mL): collagen pre-incubated with PTX3 (1μg/mL, 18 h ON 4°C), collagen pre-
incubated with PTX3 C-terminal domain (1μg/mL, 18 h ON 4°C) and collagen pre-
incubated with PTX3 N-terminal domain (1μg/mL, 18 h ON 4°C). Data shown are 
mean ± SEM; * p<0.001, n=4/group. Panel E: platelet aggregation following 
stimulation with collagen (1μg/mL, 18 h ON 4°C) and fibrinogen (0.25 mg/mL), 
collagen pre-incubated with PTX3 (1μg/mL, 18 h ON 4°C) and fibrinogen pre-
incubated with PTX3 (1μg/mL, 1 h RT), collagen pre-incubated with PTX3 C-
terminal domain (1μg/mL, 18 h ON 4°C) and fibrinogen pre-incubated with PTX3 
N-terminal domain (1μg/mL, 1 h RT). Data shown are mean ± SE; * p<0.001, n=3 
and 4/group.  
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Figure 17. Administration of human recombinant PTX3 (5mg/kg) strongly 
prevented the arterial thrombus formation induced by FeCl3, both in PTX3 KO 
and in WT mice  
Panel A: carotid artery blood flow in PTX3 KO mice injected with PBS or hPTX3 
after topic application of FeCl3 (10%); data, expressed as relative percentage to the 
value before injury, are mean ± SEM; PTX3 KO+PBS n=6, PTX3 KO+hPTX3 n=4, 
* p<0.05. Panel B: area under the curve (AUC) of carotid artery blood flow during 
30 minutes of observation after topic application of FeCl3 10% to PTX3 KO mice 
injected with PBS or hPTX3; data shown are mean ± SEM; * p<0.01. Panel C and 
D: representative hematoxylin and eosine (H/E) stained cross-sections of carotid 
arterial thrombi from PTX3 KO injected with PBS or hPTX3, scale bar=100μm. 
Panel E: carotid artery blood flow in WT mice injected with PBS or hPTX3 after 
topic application of FeCl3 (20%); data, expressed as relative percentage to the value 
before injury, are mean ± SEM; WT+PBS n=8, WT+hPTX3 n=8. Panel F: area 
under the curve (AUC) of carotid artery blood flow during 30 minutes of observation 
after topic application of FeCl3 20% to WT mice injected with PBS or hPTX3; data 
shown are mean ± SEM, * p<0.05. Panel G and H: representative hematoxylin and 
eosine (H/E) stained cross-sections of carotid arterial thrombi from WT injected with 
PBS or hPTX3, scale bar=100μm. 
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Figure 18. High fat diet (HFD) promotes the development of obesity and its related 
metabolic impairments (I)  
Panel A: weight gain (g) of wild type mice fed with the HFD or standard fat diet 
(SFD for 20 weeks); data are presented as mean of weight gain per week ± SEM; ** 
p<0.01, n=10/group. Panel B: area under the curve of weight gain versus time (a.u.) 
of wild type fed with HFD and SFD for 20 weeks; data are presented as mean of 
AUC/mouse ± SEM; ** p<0.001, n=10/group. Panel C: food intake (g) of wild type 
fed with HFD and SFD; data are mean of the average of food intake/day monitored 
for two weeks ± SEM; n=10/group. Panel D: glucose tolerance test performed after 
10 weeks of diet in wild type fed with HFD and SFD; data are presented as mean of 
glucose concentration/mouse checked before glucose injection (2 mg/g) and after 15, 
30, 60, 90 and 120 minutes ± SEM; *** p<0.001, ** p<0.01, * p<0.05; n=10/group. 
Panel E: area under the curve of glucose concentrations during GTT performed in 
wild type fed with HFD and SFD; data are presented as mean of AUC/mouse ± 
SEM; ** p<0.05, n=10/group.   
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Figure 19. High fat diet (HFD) promotes the development of obesity and its related 
metabolic impairments (II)  
Panel A: area under the curve of weight gain versus time (a.u.) of wild type fed with 
HFD for 10 or 20 weeks; data are presented as mean of AUC/mouse ± SEM; ** 
p<0.001, n=5/group. Panel B: basal glycaemia after an overnight fasting in wild type 
fed with HFD for 10 or 20 weeks; data are presented as mean of basal 
glycaemia/mouse ± SEM; ** p<0.01, n=5/group. Panel C: insulin tolerance test 
performed in wild type mice fed with HFD for 10 and 20 weeks; data are presented 
as mean of glucose concentration/mouse checked before insulin injection 
(0,1mU/µL) and after 15, 30, 60, 90 and 120 minutes ± SEM; *** p<0.001, ** 
p<0.01, * p<0.05; n=5/group. 
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Figure 20. PTX3 deficiency protects from diet-induced obesity 
Panel A: body weight (g) of WT and PTX3 KO mice fed with HFD for 20 weeks; 
data are presented as mean of body weight; n=10/group. Panel B: weight gain (g) of 
WT and PTX3 KO mice fed with the HFD for 20 weeks; data are presented as mean 
of weight gain per week ± SEM; * p<0.05, n=10/group. Panel C: area under the 
curve of weight gain versus time (a.u.) of WT and PTX3 KO fed with HFD for 20 
weeks; data are presented as mean of AUC/mouse ± SEM; * p<0.05, n=10/group. 
Panel D: food intake (g) of WT and PTX3 KO mice fed with HFD; data are mean of 
the average of food intake/day monitored for two weeks ± SEM; n=10/group. 
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Figure 21. PTX3 deficiency does not impair glucose and insulin tolerance 
Panel A: basal glycaemia after an overnight fasting in WT and PTX3 KO mice fed 
with HFD for 10 weeks; data are presented as mean of basal glycaemia/mouse ± 
SEM; n=10/group. Panel B: basal glycaemia after an overnight fasting in WT and 
PTX3 KO mice fed with HFD for 10 weeks; data are presented as mean of basal 
glycaemia/mouse ± SEM; n=10/group. Panel C: glucose tolerance test performed 
after 10 weeks of diet in WT and PTX3 KO fed with HFD; data are presented as 
mean of glucose concentration/mouse checked before glucose injection (2 mg/g) and 
after 15, 30, 60, 90 and 120 minutes ± SEM; n=10/group. Panel D: glucose tolerance 
test performed after 20 weeks of diet in WT and PTX3 KO fed with HFD; data are 
presented as mean of glucose concentration/mouse checked before glucose injection 
(2 mg/g) and after 15, 30, 60, 90 and 120 minutes ± SEM; n=10/group. Panel E: 
insulin tolerance test performed at 10 weeks in WT e PTX3 KO mice fed with HFD; 
data are presented as mean of glucose concentration/mouse checked before insulin 
injection (0,1mU/µL) and after 15, 30, 60, 90 and 120 minutes ± SEM; n=10/group. 
Panel F: insulin tolerance test performed at 20 weeks in WT e PTX3 KO mice fed 
with HFD; data are presented as mean of glucose concentration/mouse checked 
before insulin injection (0,1mU/µL) and after 15, 30, 60, 90 and 120 minutes ± SEM; 
n=10/group. 
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Figure 22. PTX3 deficiency leads to a decreased accumulation of white but not 
brown adipose tissue 
Panel A: area of visceral (VAT) and subcutaneous (SCAT) adipose tissue of WT and 
PTX3 KO mice fed with HFD for 10 weeks obtained through magnetic resonance for 
imaging (MRI); data are presented as mean of 3 sections/mouse ± SEM; p<0.05, 
n=5/group. Panel B: area of visceral (VAT) and subcutaneous (SCAT) adipose 
tissue of WT and PTX3 KO mice fed with HFD for 20 weeks obtained through MRI; 
data are presented as mean of 3 sections/mouse ± SEM; p<0.05, n=7/group. Panel C: 
representative transversal pictures of mouse abdomen from MRI software at 10 
weeks of HFD. Panel D: representative transversal pictures of mouse abdomen from 
MRI software at 20 weeks of HFD.  Panel E: area of brown adipose tissue (BAT) of 
WT and PTX3 KO mice fed with HFD for 10 weeks obtained through MRI; data are 
presented as mean of 3 sections/mouse ± SEM; p<0.05, n=5/group. Panel F: area of 
brown adipose tissue (BAT) of WT and PTX3 KO mice fed with HFD for 20 weeks 
obtained through MRI; data are presented as mean of 3 sections/mouse ± SEM; 
p<0.05, n=5/group. Panel G: representative transversal pictures of mouse cervical 
region from MRI software at 20 weeks of HFD.   
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Figure 23. PTX3 deficiency is associated with a decreased area of adipocytes in the 
visceral but not in the subcutaneous adipose tissue 
Panel A: area of adipocytes from visceral adipose tissue (VAT) of WT and PTX3 
KO mice after 20 weeks of diet; data are presented as mean of adipocyte area/VAT 
section of mouse ± SEM; p<0.01; n=10/group. Panel B: area of adipocytes from 
subcutaneous adipose tissue (SCAT) of WT and PTX3 KO mice after 20 weeks of 
diet; data are presented as mean of adipocyte area/SCAT section of mouse ± SEM; 
p<0.01; n=10/group. Panel C: representative hematoxylin and eosine (H/E) stained 
cross-sections of VAT from WT and PTX3 KO mice at 20 weeks of diet. Panel D: 
representative hematoxylin and eosine (H/E) stained cross-sections of SCAT from 
WT and PTX3 KO mice at 20 weeks of diet.  
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Figure 24. PTX3 deficiency is associated with a decreased inflammation of visceral 
adipose tissue 
Panel A: leukocyte infiltrated in VAT of WT and PTX3 KO mice; data are presented 
as mean of counted leukocytes/g of VAT ± SEM; p=0.08; n=5/group. Panel B: 
expression of cytokines in VAT of WT and PTX3 KO mice; data are presented as 
fold of expression compared to WT and corrected on RLP gene; p<0.05, n=10. 
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